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General introduction
Definitions of COPD, asthma and airway obstruction.
This	paragraph	discusses	the	definitions	of	Chronic	obstructive	pulmonary	
disease (COPD), asthma and airway obstruction. First of all, according to 
the	World	Health	Organization,	COPD	is	defined	as:	“Chronic	obstructive	
pulmonary disease (COPD) is a lung disease characterized by chronic 
obstruction	 of	 lung	 airflow	 that	 interferes	 with	 normal	 breathing	 and	
is not fully reversible. The more familiar terms ‘chronic bronchitis’ and 
‘emphysema’ are no longer used, but are now included within the COPD 
diagnosis.	COPD	is	not	simply	a	“smoker’s	cough”	but	an	under-diagnosed,	
life-threatening	lung	disease.	[1]”.	This	definition	differs	substantially	from	
the	definition	of	the	American	Thoracic	Society	and	European	Respiratory	
Society	(ATS-ERS)	which	resembles	the	definition	of	the	Global	Initiative	
for	Obstructive	 Lung	Disease	 (GOLD):	 “Chronic	 obstructive	 pulmonary	
disease (COPD) is a preventable and treatable disease characterized by 
airflow	limitation	that	is	not	fully	reversible.	The	airflow	limitation	is	usually	
progressive	 and	 is	 associated	 with	 an	 abnormal	 inflammatory	 response	
of the lungs to noxious particles or gases, primarily caused by cigarette 
smoking.	Although	 COPD	 affects	 the	 lungs,	 it	 also	 produces	 significant	
systemic	consequences.”[2,3]
Secondly,	 the	 Global	 Initiative	 for	 Asthma	 (GINA)	 defines	 asthma	 by	
its clinical, physiological and pathological characteristics. The main 
physiological feature of asthma is episodic airway obstruction characterized 
by	expiratory	airflow	limitation	[4].
Finally	 the	 definition	 of	 airway	 obstruction	 is	 disputed	 by	 the	ERS-ATS	
and the GOLD. The ATS-ERS states that obstruction is present when the 
forced	expiratory	volume	in	the	first	second	(FEV1)	and	FEV1/VC	(Vital	
Capacity) are both smaller than the lower limits of normal (LLN), being 
1.64 * SD of the Residual Standard Deviation [5]. The GOLD guideline 
postulates	that	a	post	bronchodilator		FEV1/FVC	(Forced	Vital	Capacity)	
smaller	than	0.7	confirms	the	presence	of	airflow	limitation	that	is	not	fully	
reversible [3].
The	fact	that	the	GOLD	definition	of	obstruction	with	fixed	limits	may	lead	
to a bias in the diagnosis of COPD has already been recognized [5,7,8].  In 
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this	thesis	we	will	use	the	ERS-ATS	definition	of	obstruction	as	postulated	
by Pellegrino et al [5]. It is however surprising and confusing that in another 
document	of	the	ATS-ERS,	the	fixed	ratio	of	FEV1/FVC	of		0,7	is	adopted	
from	 the	GOLD	guidelines	 [3].	Nevertheless,	 based	on	 these	definitions,	
pulmonary function tests are mandatory for making the diagnosis on the 
obstructive lung diseases Asthma and COPD.
Discussion on severity of COPD 
Several	 classifications	 have	 been	 developed	 according	 to	 the	 severity	 of	
COPD.	 The	 GOLD	 guideline,	 for	 instance,	 uses	 a	 simple	 classification	
based	on	FEV1	as	the	percentage	of	the	predicted	value.	This	classification	
is shown in Table 1.
Table 1
However,	this	classification,	as	well	as	the	ATS-ERS	spirometric	classification	
[3], is not a very good predictor for prognosis of life expectancy  nor for the 
disease burden in a single patient [9,10], since additional factors, which may 
influence	lung	function,	are	not	taken	into	account.	These	factors	include	
other lung function parameters, transfer capacity of carbon monoxide, 
exercise tests, health status, dyspnea measurements, exacerbation frequency 
and the level of emphysema measured by CT-scanning and biomarkers (in 
exhaled air or condensate of exhaled air and blood). In order to make a better 
prediction of life expectancy, the bode index is introduced [9,11]. Bode 
is an acronym for Body mass index, Obstruction, Dyspnea  and Exercise 
measured by the six minutes walking test. Nevertheless, this instrument  is 
not able to accurately predict life expectancy nor the end of a life phase of a 
subject	with	severe	COPD	[12].		In	this	thesis	we	use	the	GOLD	definition	
on severity of COPD because of its simplicity.
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Expiratory versus inspiratory parameters
FEV1 is a very important and widely used expiratory lung function 
parameter.	It	is	used	as	a	measure	of	severity	of	airflow	obstruction,	to	test	
airway hyperresponsiveness and to test airway reversibility. It is, however, 
disappointing that this expiratory parameter does not correlate well with the 
dyspnea feeling of the patient. Dyspnea is one of the major complaints in 
subjects with COPD. The weak association between the change in dyspnea 
and the change in FEV1 or FVC after the use of bronchodilators [13-16] 
may be due to 
1. Airway compression during forced expiration 
2. The absence of dyspnea in rest in patient with stable COPD,  and 
therefore an inability to improve after the use of  bronchodilators.
Inspiratory	 parameters	 like	 Forced	 Inspiraty	 Volume	 in	 the	 first	 second	
(FIV1),	 however,	 are	 not	 influenced	 by	 the	 above	 mentioned	 airway	
compression. Therefore we are interested in the value of inspiratory 
parameters in the management of COPD. Inspiratory parameters could be 
more sensitive to interventions like bronchodilators because the airway 
collapse	during	forced	expiration	may	obscure	benefits	of	the	interventions.	
In the literature, O’Donnel and Taube [16,17]give support for the idea 
that	 inspiratory	 parameters	 may	 be	 more	 sensitive	 to	 find	 significant	
improvements after bronchodilators in patients with COPD. Inspiratory 
parameters can be obtained after a fast expiration (Fe) or after a slow 
expiration (Se). However, it is not clear yet which of these two methods 
would be best in order to measure inpiratory parameters. Therefore we 
compared these methods and presented the results in chapter two.
Reversibility and random variation
Another important item to discuss  is the reversibility or responsiveness (we 
use these terms interchangeably in this thesis) of lung function parameters 
after an intervention like bronchodilation or pursed-lips breathing (PLB). 
There is  no consensus about the way to express reversibility, not even for the 
most known parameter i.e. FEV1 [5]. On the other hand there is consensus 
that reversibility within one subject must exceed the random variation= 
natural variation for that parameter [5]. The random or natural variation can 
be represented in a so called Bland-Altman plot[18]. To understand these 
plots we present in Figure 1 a simple example and Figure 2 an illustration 
of two different types of scatter.
11
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Figure 1. A simple example of a Bland Altman plot.
Patient A, a man with severe COPD was tested two times with a 
time interval of one hour, he had on both occasions an FEV1 of 0,5 
L. (horizontal axis 0,5 L and vertical axes no difference=0. Patient 
B a women had a FEV1 0f 1 L the first time and 1.2 L an hour later 
(horizontal axis FEV1 1,1 L being the average of 1 and 1,2 L, snd 
+ 0.2 on the vertical axis). Patient, C a man with moderate COPD 
expires the first time a FEV1 of 2 L one hour later 1,8 L (difference 
-0,2 L  on the vertical axis and 1,9 L on the horizontal axis). In real a 
study has to be done with some hundreds of test-retest measurements 
in order to visualize the scatter for the natural variation in subjects 
with COPD. If the  mean scatter is the same on all values of the FEV1 
(horizontal axes), this is called a homoscedastic scatter. But it is also 
possible that f.e. the mean scatter is increasing when the FEV1 value 
increases, this is called a heteroscedastic scatter. The latter is actually 
unwanted because for each patient with another FEV1 there is also 
another magnitude for the natural scatter.
12
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Figure 2 is an illustration of these two different types of scatter.
Figure 2. Bland and Altman plots with theoretical types of scatter. 
The vertical axis shows the test (T) retest (R) difference (R-T); the horizontal axis 
shows the average (T+R/2). Each point corresponds with one test-retest pair. 
Left panel: dataset with a random scatter not dependent on the parameter value. 
Right panel: same dataset, but now the percent change from the average 
parameter value is shown; the scatter is highly dependent on the parameter 
value. In the left panel, the scatter can be described with just one value, 
e.g., the coefficient of repeatability (CR). In the right panel, the scatter 
cannot be precisely described with one value because the scatter on the 
low and high parameter values will not precisely reflect a fixed CR. Thus, 
for describing random variation, a homoscedastic scatter is preferred.
Reversibility can be expressed in different ways 
•	 Absolute difference i.e. in liters, the ATS-ERS taskforce choose for at 
least 200 ml improvement in FEV1 as a part of their reversibility criterion 
but they acknowledge that there is no consensus about this [5] . 
•	 Percentage of predicted value 
•	 Percentage of initial value, the ATS-ERS taskforce recommend also at 
least 12% increase with respect to initial value [5]. 
The magnitude of the scatter of random variation can also depend on the 
initial parameter value. Therefore, not only the magnitude but also the 
type (homoscedastic or heteroscedastic) scatter has to be known. In the 
literature, recommendations on the method to be used to detect the type of 
scatter of a parameter have been published [5,18], but  to our knowledge 
13
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no literature is available that implements this method for lung function 
parameters. For the magnitude of the scatter there is an advice to use the 
coefficient	of	repeatability	instead	of	the	more	commonly	used	coefficient	
of variation [18]. The implementation of this method for detecting the type 
and magnitude of the scatter  for FEV1 is described in  chapter three and in 
chapter four this is done for different inspiratory  lung function parameters.
Treatment goals for COPD 
In general, treatment goals for patients with COPD aim to improve 
the prognosis and the quality of life. To improve the quality of life and 
consequently to minimize the burden of disease, several treatment options 
are available. Besides the most important treatment options, including giving 
up smoking, exercise training and maximal bronchodilatation,  pursed lips 
breathing (PLB) is one of the treatment options.
 ThePursed lips breathing technique in which the patients expires quietly 
with nearly closed lips is used as an item of patient education in rehabilitation 
programs [19,20]. PLB may improve pulmonary gas exchange [21,22], 
reduces	the	breathing	frequency	(BF)	and	decreases	hyperinflation	[23,24].	
A decrease in dyspnea and an increase in tidal volume are other consequences 
of PLB in patients with moderate-to-severe COPD [20]. Additionally, a 
faster recovery from dyspnea and a slower respiratory rate were found after 
walking with PLB [25]. Because of the importance of inspiratory parameters 
in this thesis, we studied the effects of  PLB on these parameters. In chapter 
five	we	describe	 the	effect	of	PLB	in	patients	with	severe-to-very-severe	
COPD (GOLD stages III and IV) on inspiratory parameters as well as FEV1, 
forced vital capacity (FVC), oxygen saturation, end-tidal CO2 tension (ET-
CO2), BF, and dyspnea. In chapter six we discuss our results of short acting 
bronchodilator use on inspiratory parameters. 
Optimal lung function testing. 
Finding the optimal diagnostic work-up in patients with obstructive lung 
disease is challenging and will be discussed in chapter six. A physician who 
routinely orders generously PFTs in the work-up of patients runs the risk of 
unnecessary testing. However, a physician who orders tests more sparingly 
runs the risk of unnecessary outpatient visits. In view of the high incidence 
of	patients	with	obstructive	lung	diseases,	it	is	important	to	find	the	optimal	
diagnostic work-up in each of these patients. To this end, we have developed 
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a diagnostic protocol that can be jointly used by physicians and pulmonary 
function assistants. In chapter 6 we examined whether following a PFT 
protocol is more cost effective than the classical way of test ordering.
Aim and outline of this thesis.
In chapter two we aim to formulate recommendations for the measurement 
of the FIV1 manoeuvre in COPD patients by focusing on the following 
items:
(1) The difference in FIV1 when performed after a slow (FIV1-Se) or a fast 
(FEV1-Fe) expiration and its relation to the severity of COPD.
(2) The correlation between, and interchangeability of, FIV1-Se and FIV1-Fe.
(3) The variability of FIV1-Se and of FIV1-Fe and its dependence on the 
severity of COPD.
(4) The optimal number of FIV1-Se manoeuvres in order to get an acceptable 
value for the FIV1, and whether this number is dependent on the severity 
of COPD.
In chapter three we will investigate which type and magnitude of scatter 
applies to the (absolute and percent) changes in FEV1. Thereafter, we will 
hold these result against the recommendation of the ERS-ATS taskforce for 
interpretative strategy of PFT’s 
In chapter four we will investigate which type of scatter applies to the 
(absolute and percent) changes in inspiratory parameters (FIV1, Inspiratory 
Capacity (IC), Peak Inspiratory Flow (PIF) and Maximal Inspiratory Flow 
at	50%	(MIF50)).	Next,	we	determine	the	coefficient	of	repeatability	(CR)	
for the given parameters. 
In chapter five we will evaluate the effect of pursed lips breathing (PLB) 
in patients with severe-to-very-severe COPD (GOLD stages 3 and 4) on 
inspiratory	parameters:	(forced	inspiratory	volume	in	first	second	(FIV1),	
IC,	maximal	inspiratory	flow	at	50%	of	VC	(MIF50),	and	peak	inspiratory	
flow	 (PIF))	 and	 secondary	 outcome	 parameters	 including	 FEV1,	 forced	
VC (FVC), oxygen saturation, end-tidal CO2 tension (ET-CO2), BF, and 
dyspnea
15
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In chapter six we present our results of short-acting bronchodilators and 
their effect on FEV1 and inspiratory parameters, where we also consider 
the number of patients responding for these parameters beyond the random 
variation in patients with COPD. 
In chapter seven we will explore whether protocol-driven test ordering 
reduces the number of redundant pulmonary function tests, decreases the 
number of outpatient visits, and increases the cost effectiveness of patient 
work-up in comparison to physician-driven test ordering.
In chapter eight we will summarize the results, discuss further research in 
this	field	and	make	final	conclusions	so	far.
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 Abstract
Background: In contrast to static inspiratory parameters such as vital 
capacity and inspiratory capacity, information on forced inspiratory 
volume in 1 s (FIV1) in patients with chronic obstructive pulmonary 
disease (COPD) is limited. Objectives: It was the aim of this study to 
investigate	the	influence	of	the	preceding	expiratory	manoeuvre	and	the	
optimal number of manoeuvres on FIV1 values. 
Methods: In 169 patients with COPD, FIV1 manoeuvres were performed 
after a forced (FIV1-Fe) and a slow (FIV1-Se) expiration. To investigate the 
optimal number of the FIV1-Se manoeuvres, 8 attempts were performed. 
Results: The variability of FIV1-Fe was greater than that of FIV1-Se. The 
mean difference between FIV1-Se and FIV1-Fe was 0.21 litres (p < 0.01) and 
dependent on the Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) stage. The higher the GOLD stage, the greater the difference 
between	the	2	techniques.	The	correlation	coefficient	between	FIV1-Se and 
FIV1-Fe was high (r = 0.89, p = 0.01), but there was a poor agreement 
between these parameters (limits of agreement -0.52 to 0.94 litres). Five 
manoeuvres were needed to obtain an optimal FIV1-Se. There was no 
association with the GOLD stage. 
Conclusions: In COPD patients, FIV1-Se are less variable than FIV1-Fe, 
the agreement between the 2 manoeuvres is poor, and at least 5 FIV1-Se 
manoeuvres are needed to get an acceptable FIV1. This holds for all GOLD 
stages.
21
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Introduction
The	severity	of	chronic	obstructive	pulmonary	disease	(COPD)	is	defined	
by	the	degree	of	expiratory	airflow	limitation.	It	is	essential	for	the	diagnosis	
and provides a useful description of the severity of pathological changes 
in COPD [1]. However, the impact of COPD on an individual patient 
depends not just on the degree of airway limitation but also on the severity 
of symptoms and complications of the disease. It is well known that the 
correlation between the subjective improvements in dyspnoea and increases 
in forced expiratory volume in 1 s (FEV1) after inhalation of bronchodilators 
is poor [2-5].
However,	 in	 patients	 with	 COPD	 and	 expiratory	 flow	 limitation	 at	 rest,	
changes in inspiratory and forced vital capacities (FVC) after bronchodilator 
use may be an objective tool for prescribing bronchodilators, even in the 
absence	of	a	significant	increase	in	FEV1 [5].
This was shown by Taube et al. [4] who found that in patients with severe 
COPD (mean FEV1 38% of predicted), the reduction in dyspnoea after 
inhalation	 of	 a	 β2-adrenoreceptor agonist was closely correlated with 
the change in parameters of forced inspiration, and particularly forced 
inspiratory volume in 1 s (FIV1), but not with changes in parameters of 
forced	expiration	or	hyperinflation	including	inspiratory	capacity	(IC).
In	 contrast	 with	 this	 study,	 Richter	 et	 al.	 [6]	 did	 not	 find	 significant	
improvement in FIV1 and IC after tiotropium or formoterol, but they 
commented	that	this	study	was	not	powered	to	find	significant	differences.
Newton	 et	 al.	 [7]	 characterized	 bronchodilator	 effect	 in	 terms	 of	 flow	
and volume response. Flow response was determined according to 
changes in FEV1. The volume response was ascertained by examining 
the	bronchodilator	effect	on	 IC,	 residual	volume	and	FVC.	Overall,	flow	
response	 occurred	 in	 33%	 of	 patients	 in	 the	 severe	 hyperinflation	 group	
(total lung capacity >133% of predicted value) and in 26% of patients in 
the	moderate	hyperinflation	group	(115%	<	total	lung	capacity	<	133%	of	
predicted value), and volume response occurred in up to 76% of patients 
in	the	severe	hyperinflation	group	and	in	62%	of	patients	in	the	moderate	
hyperinflation	group.
In	the	recently	published	American	Thoracic	Society/European	Respiratory	
Society	(ATS/ERS)	statement	on	clinical	pulmonary	function	testing	[8],	no	
recommendations are made for the measurement of inspriratory parameters 
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including FIV1. Therefore, it is unclear how FIV1 should be measured. 
One	 of	 the	 important	 issues	 is	 to	 define	 to	 what	 extend	 the	 expiratory	
manoeuvre	preceding	forced	inspiration	influences	FIV1. Also, the number 
of manoeuvres needed to adequately measure FIV1	is	not	specified	[9-11].	
Taube et al. [4] used a slow expiration before the measurement of FIV1, 
whereas most commercially available lung function apparatuses provide 
FIV1 after a fast expiration.
Therefore, in the present study, we aimed to formulate recommendations for 
the measurement of the FIV1 manoeuvre in COPD patients by focusing on 
the following research items.
The difference in FIV1 when performed after a slow (FIV1-Se) or a forced 
(FEV1-Fe)	expiration	and	its	relation	to	the	severity	of	COPD	as	defined	by	
the Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage.
The correlation between and interchangeability of FIV1-Se and FIV1-Fe.
The variability of FIV1-Se and FIV1-Fe and its dependence on the severity 
of COPD.
The optimal number of FIV1-Se manoeuvres in order to get an acceptable 
value for FIV1, and whether this number is dependent on the severity of 
COPD.
Material and Methods
A total of 169 consecutive patients (121 males) who met the GOLD criteria 
[1, 12] for COPD were recruited from our outpatient clinic. Inclusion criteria 
were reversibility of FEV1 <12% of predicted normal value and <200 ml [11], 
age	≥40	years,	smoker	or	former	smoker	(≥10	pack-years),	stable	disease,	
and able to perform lung function tests. Patients on oral corticosteroids or 
antibiotics in the month before inclusion, patients with symptomatic heart 
failure, respiratory diseases other than COPD, a history of asthma, allergic 
rhinitis and active cancer disease (except basal cell carcinoma of the skin) 
were excluded. The study was approved by the Hospital Medical Ethical 
Committee and all patients gave informed consent.
Study Design
Each patient was requested to discontinue all bronchodilating medications 
starting at least 24 h before execution of the tests. Before the tests, the 
3.00-litre	calibration	syringe	was	used	at	3	different	emptying	and	filling	
speeds to check linearity as recommended by the ATS and ERS standards. 
23
Recommendations from the measurement of FIV1 values in COPD 
 2
The ambient (room) temperature was measured before each test session to 
adequately perform body temperature, pressure and saturation corrections 
on	 the	 flows	 and	 volumes.	 In	 random	 order,	 the	 following	 FIV1-Fe and 
FIV1-Se techniques were performed.
To measure FIV1-Fe, patients performed as many manoeuvres as needed 
(with	a	maximum	of	8)	to	achieve	3	adequate	and	acceptable	flow	volume	
curves,	according	to	conventional	ATS/ERS	criteria	[8].	By	this	technique,	
the FIV1 is obtained after fast expiration (FIV1-Fe). For FIV1-Se, 8 maximal 
forced inspirations after a slow and maximal expiration were obtained 
(FIV1-Se). Maximal inspiration was obtained when a plateau was reached, 
or after at least 8 s duration of the inspiration.
If during the inspiratory manoeuvres VC was reached before FIV1, then 
FIV1 = VC. The largest FVC, FEV1 and FIV1 are recorded. For the predicted 
FEV1 and FVC, the normal values of the European Community for Steel 
and Coal were used [11].
To make a fair comparison between the results of FIV1-Fe versus FIV1-
Se,	the	first	3	adequate	FIV1-Fe	manoeuvres	were	compared	with	the	first	
3 adequate FIV1-Se	manoeuvres.	The	flow-volume	curves	were	measured	
with the V-MAX20 (Sensor Medics, ViaSys, Conshohocken, Pa., USA).
In order to obtain proper inspiratory parameters after a slow expiration, we 
started the measurement during slow expiration and stopped the procedure 
when the patient reached forced inspiratory vital capacity (FIVC), otherwise 
the software of the V-MAX20 rejects the obtained values.
Data Analysis
Data are presented as mean ± SD, or in the case of a non-normal distribution, 
as median and interquartile range. Differences between FIV1-Fe and FIV1-
Se were analyzed with the paired t test. One-way ANOVA and post-hoc 
multiple comparison t test (Bonferroni) were used to test differences 
between the GOLD classes. The correlation between FIV1-Fe and FIV1-Se 
was calculated by Pearson’s correlation test. The interchangeability of FIV1-
Fe and FIV1-Se was investigated as described by Bland and Altman [13]. 
We	defined	the	variability	of	FIV1-Se, FIV1-Fe and FEV1 as the difference of 
the	best	minus	the	second	best	of	the	first	3	adequate	attempts	and	expressed	
this difference as the percentage of its average. The differences of the means 
between these groups were tested with a paired sample t test. To assess 
the optimal number of FIV1 manoeuvres after a slow expiration, the best 
of 3, 4, 5 and 6 attempts was compared with the best of 8 attempts. This 
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was compared with and plotted against the percentage of failures during 
these attempts. After obtaining the optimal number of FIV1 manoeuvres, 
the effect of the GOLD stage on this optimal number in comparison with 
8 manoeuvres was examined (Spearman rank correlation). All tests used a 
2-tailed	significance	level	of	5%,	unless	otherwise	stated.	SPSS	version	11	
(2001) was used to analyse the data.
Results
In table 1, the demographic characteristics of our patients are presented.
Of	the	169	patients,	1	failed	to	perform	3	adequate	forced	expiratory	flow	
curves,	16	patients	failed	to	perform	3	adequate	inspiratory	flow	curves	after	
forced expiration, and 6 patients failed to perform 3 adequate inspiratory 
flow	 curves	 after	 slow	 expiration.	 The	 difference	 of	 6	 versus	 16	 failed	
manoeuvres of FIV1-Se versus FIV1-Fe	was	 significant	 (p	<	0.05,	 χ
2). In 
168 patients, FEV1 was 1.52 ± 0.71 litres, in 153 patients, FIV1-Fe was 2.5 ± 
0.79 litres, and in 163 patients, FIV1-Se was 2.71 ± 0.77 litres. In 79 of 153 
subjects who performed 3 FIV1-Fe manoeuvres, the FIVC was substituted 
for the FIV1. This was also done in 71 of 163 subjects who performed 3 
FIV1-Se manoeuvres.
Table 1 Demographic characteristics
Data are presented as number 
of patients, with percentage in 
parenthesis, or mean ± SD.
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Difference in FIV1 when Performed after FIV1-Se or FEV1-Fe and Its 
Relation to the Severity of COPD as Defined by the GOLD Stage
Of 169 patients, 151 completed both 3 adequate FIV1-Se and 3 adequate 
FIV1-Fe manoeuvres. FIV1-Se was greater than FIV1-Fe by 0.21 litres (p < 
0.001, t test). The results of the 3 FIV1-Fe	attempts	and	the	best	of	the	first	3	
FIV1-Se attempts and their mean difference are shown in table 2
Table 2. The best of 3 attempts of FIV1-Se and FIV1-Fe and their difference
The difference between FIV1-Se and FIV1-Fe is dependent on the GOLD 
stage. 
Figure 1 presents the difference between FIV1-Se and FIV1-Fe according 
to the GOLD stage and shows that the difference for COPD stage 1 was 
4%, which rose to 16% for GOLD stage 4. The ANOVA between group test 
showed	a	significant	(p	=	0.017)	difference	for	the	relative	differences	of	
the means. The post-hoc multiple comparison t test (Bonferroni) showed 
that	the	mean	difference	in	GOLD	stage	4	differs	significantly	from	GOLD	
classes 1 and 2.
Correlation between and Interchangeability of FIV1-Se and FIV1-Fe
The	Pearson	correlation	coefficient	between	FIV1-Se and FIV1-Fe was 0.89 
(p < 0.01). However, FIV1 values obtained with the FIV1-Se and FIV1-Fe 
manoeuvres were not interchangeable. The mean difference between FIV1-
Se and FIV1-Fe was 0.21 litres, and the limits of agreement were -0.52 to 
0.94	 litres.	 In	figure	2,	we	present	 the	difference	between	 the	2	methods	
plotted against the average of the difference as described by Bland and 
Altman [13].
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Figure 1. Difference of FIV1-Se and FIV1-Fe with respect to the severity of COPD. 
The difference is expressed as percentage of the average value on the vertical axis 
versus the GOLD stage on the horizontal axis. Error bars show means ± 1.0 SE; 
the line indicates the mean.
Figure 2. Interchangeability of FIV1-Se and FIV1-Fe. On the x-axis, the mean 
FIV1 in liters is given, on the y-axis, the difference between FIV1-Se and FIV1-
Fe. Horizontal lines represent the means and the 95% confidence intervals (CI). 
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Variability of FIV1-Se and FIV1-Fe and Its Dependence on the Severity 
of COPD
FEV1 measurements were far less variable than FIV1-Fe and FIV1-Se (paired 
sample t test, p < 0.001), as can be seen in table 3.
Table 3. Variability of FIV1-Fe, FIV1-Se and FEV1 measurements
The variability between the 3 adequate manoeuvres expressed as the best minus 
the second best as percentage of their mean. IQR = Interquartile range.
FIV1-Fe showed a higher variability than FIV1-Se (paired sample t test of 
the difference, p = 0.011). To test if the variability is related to the GOLD 
class we did an ANOVA between group test for FIV1-Se (p = 0.532) and 
FIV1-Fe (p = 0.448). We found that variability was not related to COPD 
stage (table 4).
Table 4. Variability according to GOLD class
Values are expressed as 
percentage of the mean of 
the best and second 
best manoeuvre. SEM = 
Standard error of the 
mean; IQR = interquartile 
range.
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Optimal Number of FIV1-Se Manoeuvres in Order to Get an Acceptable 
Value for FIV1, and whether This Number Is Dependent on the Severity 
of COPD
Because FIV1-Se was higher and less variable than FIV1-Fe, we searched 
for the optimal number of FIV1-Se manoeuvres in order to get an acceptable 
value for FIV1-Se and investigated whether this optimal number depends on 
the GOLD stage.
The greater the number of attempts, the closer the FIV1-Se value was to 
that obtained from the best of 8 attempts (the difference is expressed as 
a	percentage	of	the	best	of	8)	(fig.	3,	line	a,	right	vertical	axis).	However,	
the greater the number of attempts, the more patients failed to perform 8 
adequate	tests	(fig.	3,	line	b,	left	vertical	axis).	We	wanted	to	find	the	number	
of attempts that gives a good compromise between the most accurate results 
and	the	maximum	number	of	patients	to	successfully	complete	the	test	(fig.	
3).
Figure 3. Percentage of failed FIV1 manoeuvres and the difference 
from the best attempt with respect to the number of attempts. Graphical 
representation of the percentage of failure of adequate inspiratory 
manoeuvres (line b, left vertical axis) and the percentage of difference of 
FIV1 from the best of 8 attempts versus the number of adequate attempts 
(line a, right vertical axis).
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We found that with 5 adequate attempts, we had a deviation from the best of 
8 attempts of 6.4% at the 95th percentile and 2.7% at the 90th percentile, so 
10% of our COPD population had a difference of 2.7% or more, and 5% of 
our population a difference of 6.4% or more from the best of 8 attempts. Of 
our COPD patients, 80.5% completed 5 or more adequate FIV1 manoeuvres 
out of 8 attempts.
We analysed the results of 5 attempts (the optimal number) with respect to 
the COPD stage (I--IV) of the patients and found no association between the 
number of inadequate efforts and the stage of disease (Spearman correlation, 
r = 0.007, p = 0.931).
Discussion
This study shows that in patients with COPD, the highest FIV1 values were 
measured after a slow expiration. The correlation between FIV1-Se and 
FIV1-Fe was high, but the limits of agreement were wide. Therefore, these 
manoeuvres are not interchangeable. The variability of FIV1-Fe was higher 
than that of FIV1-Se, and more patients failed to perform 3 adequate FIV1-Fe 
manoeuvres than 3 adequate FIV1-Se manoeuvres. Five adequate FIV1-Se 
attempts were necessary to get an optimal FIV1 value in all GOLD classes.
In this study, we have shown that the mean difference between FIV1-Se and 
FIV1-Fe was 0.21 litres. No other published comparison of the 2 methods 
for measuring FIV1 has been found. Taube et al. [4] have used FIV1 after a 
slow expiration for their study; however, they did not mention the reason for 
choosing this method. The reason for the difference between the 2 methods 
might be the airway collapse associated with a forced expiration [14]. This 
increases the physiological dead space leading to an increased end-expiratory 
volume (or residual volume). The beginning of the following inspiration is 
at a higher volume, therefore resulting in less room and a less advantageous 
length-tension relationship of the inspiratory muscles, resulting in a smaller 
FIV1 after a forced expiration. In our opinion, it is possible that after a forced 
expiration, the airway resistance increases which also causes a lower FIV1. 
Ewald	et	al.	 [15]	 found	 that	 forced	 inspiratory	capacity	was	significantly	
larger after a slow expiration than after an antecedent forced expiration by 
170 ml and he thus recommended a slow expiration but did not mention 
FIV1 or the variability of the IC.
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In this study, we provide evidence that the mean difference between FIV1-
Se and FIV1-Fe was dependent on the GOLD stage; the lower the FEV1, 
and thus the higher the GOLD stage, the greater the difference between 
FIV1-Se and FIV1-Fe. This is what we expected: the more severe the COPD, 
the greater the airway collapses after forced expiration, and therefore, the 
greater the difference between these manoeuvres. We have not found this 
published in literature before.
The present study shows that the values of FIV1-Se and FIV1-Fe were not 
interchangeable because of the poor limits of agreement between these 
manoeuvres (mean difference 0.21 litres, limits of agreement -0.52 to 0.94 
litres). We found that of 9 outliers (as seen in the Bland-Altman plot), 7 
were in the higher range. This might be because of very collapsible airways. 
The 2 outliers on the lower side might have upper airway collapsibility as 
seen for instance in patients with obstructive sleep apnoea syndrome.
Despite the poor agreement, we found a good correlation between FIV1-Se 
and FIV1-Fe (Pearson, r = 0.89, p < 0.01). This is not surprising, because we 
are dealing with the same parameter, namely FIV1.
Our results indicate that the variability of FIV1-Se	was	significantly	smaller	
(paired sample t test, p = 0.011) and had less dispersion than that of the 
FIV1-Fe	(median	3.8	vs.	4.9%).	This	finding	is	important,	and	therefore,	we	
are recommending to use FIV1-Se as the method of choice. In addition, we 
found that patients failed more often in performing adequate FIV1-Fe than 
FIV1-Se manoeuvres. FEV1 shows less variability (median 2.06%) than FIV1-
Se and FIV1-Fe. We think this is because of the check valve phenomenon 
during forced expiration, which explains the effort-independent part of the 
expiration [14, 16--18]. In contrast, inspiration is fully effort dependent, 
and thus, shows variations in patient effort [14]. Other possible causes of 
variability may be that the manoeuvre is less known to both the patients and 
the pulmonary function assistants, as is the way FIV1-Se has to be performed 
on the V-MAX20 series.
As far as we know, no articles are available in literature dealing with the 
reproducibility of FIV1.	However,	we	did	find	a	study	of	Taube	et	al.	[19]	
who	 measured	 reproducibility	 as	 coefficients	 of	 variation,	 not	 within	 1	
measurement, but after bronchodilators on 3 different days. They found a 
coefficient	 of	 variation	 of	 43	 and	 45%	 for	 FEV1 and FIV1, respectively, 
after fenoterol in 13 patients with COPD. However, it is interesting that the 
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coefficients	of	variation	derived	from	FEV1 and FIV1 are close to each other. 
Probably, this rather shows the day-to-day variability of airway obstruction 
in COPD patients.
In our study, the variability did not depend on the GOLD class, and the 
ANOVA between group tests for FIV1-Se and FIV1-Fe	were	not	significant.	
This is important because FIV1-Se remains a valid reproducible test in all 
COPD	stages.	We	did	not	find	this	conclusion	in	previous	literature.
The assessment of an optimal number of FIV1 manoeuvres is complicated: 
the greater the number of manoeuvres, the more the patient tires. In patients 
with COPD, more than 8 manoeuvres might be exhausting, especially when 
the patient also has to make forced expiratory manoeuvres in order to get 
important parameters like FEV1.	It	seems	to	be	difficult	to	get	more	than	5	
adequate manoeuvres out of 8 attempts (more than 20% of COPD patients 
failed;	fig.	3,	line	b).
The difference of the best of 8 versus the best of 3, 4, 5 or 6 inspiratory 
manoeuvres	is	higher,	the	lower	the	number	of	attempts	compared	(fig.	3,	
line a). Therefore, we searched for the number of attempts that compromises 
between	tiring	of	the	patient	and	the	highest	value	(fig.	3).	Consequently,	
we recommend 5 manoeuvres of FIV1 after a slow expiration, which will 
not tire the patients and provide an acceptable difference between 5 and 8 
manoeuvres	(fig.	3).
The variability of FIV1 is higher than that of FEV1. The FEV1 manoeuvre 
has to be repeated just 3 times if the best minus the second best is <5% of 
the best or <100 ml.
There is no association (Spearman correlation 0.007, p = 0.931) between 
the number of failed manoeuvres and the Gold stage, so the amount of 
manoeuvres needed is not depended on the GOLD stage.
To better measure FIVC and FIV1-Se, the software of many spirometers will 
have to be updated. Almost all of them simply store and print the results of 
FIVC which immediately followed the ‘best’ FVC manoeuvre (or in some 
cases, the best 3 FVC manoeuvres).
In a following study, using the above-mentioned method, we will focus on 
the intraday and interday repeatability of inspiratory parameters and the 
reaction to several bronchodilators.
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Conclusions
In COPD patients, FIV1 values after a slow exhalation are higher and 
more stable than after a forced exhalation, FIV1-Se and FIV1-Fe are not 
interchangeable, more patients failed to perform 3 adequate FIV1-Fe than 
FIV1-Se manoeuvres, and at least 5 adequate FIV1-Se manoeuvres are 
needed in order to get an acceptable FIV1 (2.7% difference at the 90th 
percentile and 6.5% at the 95th percentile). This recommendation holds for 
all 4 GOLD stages.
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Abstract
Background: In patients with chronic obstructive pulmonary disease 
(COPD),	 a	 significant	 bronchodilator	 response	 must	 exceed	 the	 random	
variation (RV). Therefore, it is important that the type of scatter is 
homoscedastic, thereby reducing the chance of under or overestimating the 
RV for low or high parameter values. The aim of this study was to investigate 
the RV (type and quantity) of the forced expiratory volume in one second 
(FEV1) measurement.
Methods: spirometry was performed in 79 stable COPD patients. The 
FEV1	was	measured	five	times	in	one	day.	FEV1	values	taken	within	one	
hour	were	compared.	The	coefficient	of	repeatability	(CR)	was	calculated	
and linear regression was performed to investigate the type of scatter (i.e., 
homo- or heteroscedastic).
Results: the type of scatter was heteroscedastic for the FEV1 when the 
difference was expressed as an absolute value. However, when the difference 
was expressed as the percent change from the initial value or predicted value, 
we found homoscedastic scatter. The CR within one hour of the FEV1 was 
12% when expressed as the percent change from the initial value.
Conclusions: to obtain a more homoscedastic scatter, the percent change in 
FEV1 is a more appropriate measure than the absolute change. 
37
The one hour test-retest repeatability of FEV1 in patients with COPD 
 3
Introduction 
 
The	severity	of	chronic	obstructive	pulmonary	disease	(COPD)	is	defined	by	
the	degree	of	expiratory	airflow	limitation	[1].	After	using	bronchodilators,	
many COPD patients may experience less dyspnea but do not show 
significant	 reversibility	 in	 their	 FEV1,	 which	 is	 defined	 by	 a	 12%	
improvement from the initial value and at least 200 milliliters in volume [2]. 
However, there is no clear consensus as to how to express the reversibility of 
the FEV1 [2]. The three most commonly described methods are the percent 
change from the initial FEV1 value, the absolute change in this parameter’s 
value and the percent change from normal predicted values [2].
For	an	individual	patient	with	COPD,	a	significant	bronchodilator	response	
must exceed the random variation for the parameter of interest. Therefore, 
it is important to know the type of variation or scatter that exists for the 
parameter of interest. Figure 1 shows theoretical datasets for a test-retest 
FEV1 with different types of scatter. One dataset shows a 200 milliliter 
difference between the test and retest and the other dataset shows a difference 
of 12% from the initial value between the test and retest.
It is important to know the type of scatter for the parameter of interest. 
Typically, homoscedastic scatter is desired. The consequence of the ATS-
ERS 200 milliliter criterion as stated by Pellegrino et al., [2] dictates that 
for a patient with COPD and a FEV1 of 0.5 liter, an improvement of at least 
40% from the initial value is necessary before one may conclude that this is 
beyond random variation (Figure 1, panel B).
The importance of this 200 milliliter improvement was also raised by Hansen [3] 
and illustrated by the publication of Han et al., [4], which examined the prevalence 
of bronchoreversibility in subjects enrolled in the National Emphysema Trial. 
This later study found that only 22% of patients met the ATS-ERS criterion at 
least	once	(of	7	time	points)	and	10.2%	of	patients	met	the	criterion	at	the	first	
time point. However, if the standard of only exhibiting a 12% increase from the 
basal value was used, 452 (83%) of subjects met this criterion at least once [4]. 
The literature establishing this 200 milliliter criterion has to be scrutinized 
(see discussion section) because none of the referenced literature used the 
recommended method described by Bland and Altman [5]. 
The primary aim of this study was to investigate the type of scatter that best 
applies to the observed (absolute and percent) changes in FEV1. In addition, we 
sought	to	determine	the	coefficient	of	repeatability	(CR)	for	the	FEV1	[2,5].	
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Figure 1. Bland and Altman plots with theoretical types of scatter. The 
vertical axis shows the test (T) retest (R) difference (T-R); the horizontal axis 
shows the average (T+R)/2. Each point corresponds with one test-retest pair.
Panel A: Data set with a random scatter that is not dependent on the 
parameter value (homoscedastic). We used 200 milliliter between test and 
retest as recommended for the FEV1. 
Panel B: Same dataset, but now the percent change from the average parameter 
value is shown. The scatter is highly dependent on the parameter value. In 
panel A, the scatter can be described with just one value, e.g., the coefficient 
of repeatability (CR). In panel B, the scatter cannot be precisely described 
with one value because the scatter on the low and high parameter values 
will not precisely reflect a fixed CR (heteroscedastic). Thus, for describing 
random variation, a homoscedastic scatter is preferred. 
Panel C: Another dataset but now with a homoscedastic scatter of 12% from 
the average value.
Panel D: Represents the scatter of the same dataset but expressed as the 
absolute difference.
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Materials and methods 
A total of 79 (58 male) consecutive patients who met ATS-ERS [6] criteria 
for COPD were recruited from our outpatient clinic. These were the same 
patients we selected for a study on inspiratory parameters by Visser et al., 
[7].	The	criteria	for	inclusion	were	the	following:	patient	age	≥	40	years,	
a	 smoker	 or	 former	 smoker	 (≥10	years),	 presentation	 of	 a	 stable	 disease	
state and an ability to perform lung function tests. Excluded patients were 
those on oral corticosteroids or antibiotics in the month before the study’s 
initiation or those who had symptomatic heart failure, respiratory diseases 
other than COPD, a history of asthma, allergic rhinitis or active cancer 
(except for basal cell carcinoma of the skin). The study was approved by the 
Hospital Medical Ethical Committee and all patients gave their informed 
consent.
Methods 
Patients were asked not to use short-term bronchodilators for six to eight 
hours prior to the study and long-term bronchodilators for at least 12 hours 
before the study. Tiotropium and theophylline (b.i.d.) were not allowed for 
24 hours prior to the spirometric test.
	Lung	function	tests	were	performed	five	times	on	the	first	day	(at	9,	10,	11	
A.M. and 2 and 3 hours P.M.) and once at 9 hours A.M. over the following 
two weeks. Between these two days, the medication did not change. On the 
second day, these patients were requested to discontinue bronchodilator use 
as was done on day one.
For	expiratory	parameters,	three	suitable	flow	volume	curves	were	produced	
in	accordance	with	conventional	ATS/ERS	criteria	[8].	The	largest	forced	
vital capacity (FVC) and FEV1 were recorded. Of the retests, only the FEV1 
was recorded. For the predicted FEV1 and FVC, the normal values of the 
European Respiratory Society were used [9]. 
The	flow–volume	curves	were	measured	with	a	V-MAX20	(Sensor	Medics,	
ViaSys, Conshohocken, PA, USA).
Analysis  
The	 five	 intra-day	 lung	 function	 parameter	 data	 were	 analyzed	 with	 a	
repeated measures ANOVA followed Bonferroni’s multiple comparison 
tests.
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The type of scatter (homoscedastic or heteroscedastic) was determined by 
the method described by Visser et al., [7].
The	coefficient	of	repeatability	(CR),	as	observed	for	the	one	hour,	intra-
day and inter-day time points, was determined by the method described by 
Bland and Altman [5]. A one-tailed test was utilized to calculate the lower 
limits of normal subjects [9]. 
Results
Seventy-nine patients were included for day one (intra-day measurements) 
and 76 were measured again within the following two weeks. For two 
patients, we were unable to have an appointment within the two week 
period. In addition, in one patient, there was an exacerbation. The baseline 
patient characteristics are summarized in Table 1.
Table 1. Characteristics of the COPD patient group
COPD= Chronic Obstructive Pulmonary Disease; BMI= Body Mass Index; 
FEV1=Forced Expiratory Flow in one second; GOLD= Global Initiative for 
Chronic Obstructive Lung Disease (stage 1, 2, 3 or 4).
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The	 intra-day	mean	 and	 SD	 values	 did	 not	 differ	 significantly	 (repeated	
measures ANOVA) on different occasions for this day (see Table 2). 
Therefore, we took three pairs of measurements for each patient with a one 
hour	 difference	 (9–10,	 10–11	 and	 14–15	 hours)	 for	 determination	 of	 the	
type	of	scatter	and	the	one	hour	coefficient	of	repeatability.
Table 2. Mean and (SD) values of the FEV1 on five occasions during  
the day
FEV1=Forced Expiratory Flow in one second.
The type of scatter for the FEV1 
The scatter of the one hour differences in FEV1 versus the average FEV1 
value across the two time periods is shown in Figure 2, 
42
Chapter 3
Figure 2. Panel A: Bland–Altman plot showing the absolute difference of FEV1 
versus the average, which shows a heteroscedastic scatter of the FEV1. 
Panel B: Absolute difference of FEV1 versus average FEV1 plus linear regression, 
which shows a slope in the regression line. 
Panel C: Difference FEV1 now presented as the percentage of the average value, 
which shows a homoscedastic scatter. 
Panel D: Percentage difference of FEV1 versus average FEV1 plus linear 
regression, which shows a flat slope of the regression line, which is not 
significantly different from zero.
Panel E: Difference of FEV1 as percentage of predicted FEV1.
Panel F: Absolute difference of FEV1 as percentage of predicted FEV1 plus linear 
regression line showing a homoscedastic scatter. 
The dashed lines in panel B and D and F represent the confidence interval of the 
regression line.
Panel A. The scatter becomes wider when the average FEV1 increases. 
Panel B presents the same data except that negative difference values 
are	made	positive	and	a	linear	regression	line	is	added	to	the	figure.	The	
regression	line	is	not	flat	(P<0.0001),	which	would	be	the	case	if	the	
scatter was independent of the FEV1 (Table 3).
On the other hand, when the difference in FEV1 is expressed as a percentage 
of the average FEV1 (Figure 2, panel C) or as a percentage of the predicted 
FEV1 (Figure 2, panel E), an evenly distributed scatter can be seen along 
the whole range of the average FEV1. The slope of the linear regression 
line	is	now	nearly	flat	(Figure	2,	panels	D	and	F)	and	is	not	significantly	
different from zero (Table 3). 
Table 3. Linear regression: standardized slopes (r) and P values; tests 
whether the slope is significantly different from zero  N=237
FEV1=Forced Expiratory Flow in one second; FEV1% initial=FEV1 as 
percentage form initial value; FEV1%pred=FEV1 as percentage form 
predicted value. See also Figures 2 and 3 and the text for further explanation.
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The random variability presented by the coefficient of repeatability
The	coefficients	of	repeatability	for	FEV1	are	graphically	presented	in	the	
Bland and Altman plots in Figure 3. The spread around the solid line (no 
difference)	can	be	seen	and	the	coefficient	of	repeatability	is	presented	by	
the dotted line with ±1.64 × standard deviation. The spread appears to be 
relatively even, thereby indicating homoscedascity. 
Figure 3. Left panel: Bland–Altman plot of the percentage difference versus 
the average of the FEV1. The coefficient of repeatability (CR) corresponds 
with the dotted lines (e.g., the coefficient of repeatability is 11.8%, which is 
1.64x SD). Right panel: Blant-Altman plot of the percentage difference of the 
FEV1 to the normal predicted value versus the average FEV1. The coefficient 
of repeatability is 7.8%.
In	 Table	 4,	 the	 results	 of	 the	 coefficients	 of	 repeatability	 (CR)	 are	
summarized. The FEV1 presented as a percentage of the predicted value 
shows	a	coefficient	of	repeatability	of	7.8%	(Figure	3).	In	addition,	the	one	
hour	coefficients	of	repeatability,	the	5	hour	and	the	between	day	coefficients	
of repeatability are summarized for the FEV1 percent change from initial 
values (Table 4).
Table 4. Coefficients of repeatability (CR) retested after one hour 
(n=237), after five hours (n=79) and after 3-8 days (n-76)
FEV1=Forced Expiratory Flow in one second; FEV1% initial=FEV1 as 
percentage form initial value; FEV1%pred=FEV1 as percentage form 
predicted value.
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Discussion
Type of scatter
This study shows that within the same subject, the one hour difference in 
FEV1 can be more appropriately expressed as the percentage of the initial 
value or the percentage of the predicted value rather than merely as the 
difference between these two values. Notably, both percentage methods 
produce a more homoscedastic scatter. The measured FEV1 showed a 
scatter	 that	 was	 significantly	 dependent	 on	 the	 average	 parameter	 value	
(Figure 2, panels A and B and Table 3). Consequently, these data appear 
heteroscedastic if we present these differences as liters. On the other hand, 
if we represent the difference as the percentage of the average value (which 
was similar to the initial value) or as the percentage of the predicted value, 
we	found	no	significant	dependence	on	the	FEV1	value.	
Several studies have addressed the variability of lung function parameters, 
which is especially evident with forced expiration [10-14]. However, these 
studies	used	 the	variation	coefficient	 instead	of	 the	method	described	by	
Bland and Altman [5]. Therefore, the type of spread was not investigated. 
According to the ATS-ERS, the method of Bland and Altman is described 
as the preferred method for investigating random variation and this method 
allows the type of spread to be readily visible [2,5].
Studies mentioned by Pellegrino et al., [2] are described in the following 
text and abstracted in Table 5.
References made to studies with measurements of bronchodilator responses 
in normal and healthy subjects are not relevant to the context of random 
variation among patients with COPD because they neither described the 
population of interest nor the random variation [15-17]. However, the study 
of Dales at al., [16] is worth mentioning because they found that among 2609 
healthy subjects with an FEV1 greater than 80% of the predicted value the 
upper limit of improvement (to terbutaline) was 9% of the predicted normal 
value. Therefore, more than a 9% improvement of the predicted normal 
value after bronchodilator administration can be seen as an indication of 
reversibility in this group. However, examining random variation in patients 
with COPD in this publication was not done in this publication.
Pellegrino	et	al.,	[18]	focused	on	the	partial	forced	expiratory	flow	volume	
curves after bronchodilators in 78 patients, 50 asthmatics and 28 COPD 
patients. In that study, only 26 subjects were tested with placebo and the 
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number of asthmatics and COPD patients that were included was not 
reported. Of these placebo tested patients, the authors mentioned the mean 
test retest difference (1%) and the SD (7%). However, they did not use 
the method described by Bland and Altman and did not report the type of 
scatter. 
Anthonissen et al., [10] tested 985 patients with COPD after bronchodilators. 
There were no test-retest or placebo groups used in this study so there were 
no data examining random variation. Therefore, the remarks on the type of 
scatter were not relevant for the assessment of random variation.
Sourk et al., [14] tested 40 subjects with placebo and 72 with bronchodilators. 
Of	the	40	placebo	tested	patients,	 they	presented	the	confidence	intervals	
of	the	test–retest	differences	as	a	percentage	of	the	initial	value	and	as	an	
absolute difference. However, they did not investigate the type of scatter.  
 Tweeddale et al., [19] tested 150 patients with obstructive lung diseases 
(asthma and COPD), which included a test-retest after 20 minutes. They did 
not use the method described by Bland and Altman but divided the obstructed 
patients into the three following subgroups by their average FEV1: group A, 
0.5-1.1 liter; group B, 1.15-2.4 liter; group C, greater than 2.45 liter. They 
found	significantly	different	values	for	the	SD	of	the	test-retest	differences	
when expressed as a percentage of the predicted value (Levine test) and no 
significant	difference	was	found	between	these	groups	when	the	absolute	
difference was taken into account. Thus, their results are in contrast with 
our	findings.	However,	they	used	a	different	method	without	visualizing	the	
test-retest scatter, a different patient population and a different time interval. 
In addition, 150 data points were examined in this previous, while 237 data 
points were included in our study.
Enright et al., [20] described the short-time repeatability of FEV1 but they 
examined this variable only with one prebronchodilator test and took the 
difference between the highest and second highest FEV1 value.  Furthermore, 
only 9.5% (170 subjects) of their study population was mentioned to have 
COPD (and 11% had asthma) and the rest of the patient population was not 
described. They also did not perform a test on the type of scatter (homo or 
heteroscedastic), which is of the utmost importance as we have described 
in this article. 
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Table 5. Abstract of references used for the latest official ATS-ERS 
recommendation for improvement of FEV1 after bronchodilators
Thus, none of these previous studies used the recommended Bland and 
Altman method for describing test-retest results for random variation and 
the only study that investigated the type of scatter (by the Levine test) used 
a mixed patient population. Therefore, we believe that our study provides 
the strongest evidence that the type of random scatter for FEV1 is best 
revealed if the test values are expressed as a percent change among patients 
with COPD. Consequently, we think that the recommendation of at least a 
200 milliliter absolute difference [2] may be reconsidered. 
Although	 we	 are	 reporting	 statistically	 significant	 improvements,	 the	
clinical	relevance	 is	difficult	 to	establish	because	of	 the	weak	correlation	
between dyspnea and FEV1 changes after bronchodilators. If we repeatedly 
find	no	significant	improvement	within	a	subject,	we	may	be	observing	a	
placebo effect. 
The	practical	consequence	of	this	finding	is	that	more	patients	with	serious	
COPD can be considered responders to bronchodilators when we use the 
criterion of 12% of the initial value (or 8% of the predicted value) and omit 
the 200 milliliter absolute response standard.
Random variability
The one hour repeatability was by far the most important for random 
variability because most interventions of interest (such as bronchodilator 
response) can be measured within one hour. Subjects must exceed this level 
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of random variation before it can be decided that an improvement of an 
intervention can be attributed to that intervention. 
We decided to pool our patient data (with one hour differences measured at 
three time points a day per patient) to obtain more data points and, thus, more 
reliable	results.	This	pooling	was	possible	because	we	found	no	significant	
differences	between	the	group	means	and	spreads	as	well	as	no	significant	
differences in the parameters for measurements between 9 a.m. and 2 p.m. 
This result may be in contrast with Calverley et al., [21] and van Noord et 
al.,	[22]	who	found	significantly	lower	values	at	3	and	6	a.m.;	however,	we	
did not perform measurements at these hours.
We	chose	the	CR	instead	of	the	more	popular	variation	coefficient	because	it	
more	precisely	reflects	repeatability	and	provides	a	graphical	representation	
of the type of scatter, which has been stated by Bland and Altman [5] and 
adheres to the recommendations of the ERS-ATS committee [2].
The intra-day	coefficients	of	repeatability	are	important	to	know	when	we	
are performing interventions that take more than one hour, i.e., medications 
such as theophylline, tiotropium or other interventions that take more time 
to retest.
We selected the 9 to 14 hour difference because the FEV1 group’s mean did 
not	change	during	this	interval.	There	was	a	small	but	significant	decrease	
in FEV1 during the 9 to 15 hour interval (Table 2); therefore, we took the 9 
to 14 interval as our difference. We think that this decrease may be due to 
the	fact	that	patients	at	the	end	become	tired	of	repeating	the	procedure	five	
times a day, which is compounded in the meantime by not being allowed 
to take any bronchodilator drugs; moreover, there may have been some 
circadian effect [21,22]. The higher CR value, compared to the one hour 
value, is expected due to the larger time interval. 
The inter-day random variability improvements of interventions taking 
more than one day can be considered as beyond random variation when 
the above-mentioned improvements are taken into account. Between the 
two days, patients did not change their medication and no exacerbations 
occurred. Another supporting point of this inter-day CR was that we were 
unable to see all of the patients on an exact inter-day interval of one week 
because we were limited by when our patients were able to visit our outpatient 
department. As the smallest interval was three days and the largest interval 
was eight days, analyses were all conducted within two weeks. In general, 
the longer the interval between the two measurements (from one hour to 
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several days), the higher the CR obtained. This result may be caused by the 
longer time period due to weather or other environmental factors affecting 
patient accessibility.
Limitations of this study
Subjects	in	this	study	included	only	patients	with	COPD,	so	our	findings	do	
not extend to normal patients or those with asthma or restrictive diseases. In 
addition, the random variation within these groups may have been different. 
We used all data (including outliers) to construct the Bland and Altman plots; 
however,	small	sample	sizes	can	influence	the	linear	regression	analysis	of	
the transformed Bland and Altman plots when the outliers are in the lower 
or upper zones of the average parameter value.
Conclusions
Random variation of FEV1 is less dependent on changing parameter values 
when presented as a percentage of the initial value or the predicted value 
than as the absolute difference. 
In individual patients with COPD, their improvement after intervention 
must	exceed	the	given	coefficients	of	repeatability.	
We think the 200 milliliter criterion as stated by the ERS may be reconsidered. 
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 Abstract
Background: In chronic obstructive pulmonary disease (COPD), the 
response of the forced expiratory volume in 1 second (FEV1) after 
bronchodilator application is weak. Inspiratory parameters like the forced 
inspiratory volume in 1 second (FIV1) and inspiratory capacity (IC) can 
be responsive to bronchodilators. In an individual patient with COPD, 
a	 significant	 bronchodilator	 response	 must	 at	 least	 exceed	 the	 random	
variation for that parameter. Therefore, it is important that the type of scatter 
is homoscedastic, as the chance of underestimating or overestimating the 
random variation for low or high parameter values is minimized. The aim 
of this study is to investigate the random variation (type and quantity) of 
inspiratory parameters. 
Methods: In 79 stable COPD patients, spirometry was performed.
 The forced inspiratory volume in 1 second (FIV1), inspiratory capacity (IC), 
maximal	inspiratory	flow	at	50%		(MIF50)	and	peak	inspiratory	flow	(PIF)	
were	measured	five	times	in	one	day	and	again	within	two	weeks	of	the	first	
measurement. The values of these parameters, taken within one hour, within 
one	day	and	between	two	different	days,	were	compared.	The	coefficient	of	
repeatability (CR) was calculated, and, in addition, linear regression was 
performed to investigate the type of scatter (homo- or heteroscedastic) of 
the measured parameters.
Results: The type of scatter was heteroscedastic for all of the parameters 
when the differences were expressed as absolute values; however, when the 
differences were expressed as the percent change from the initial values, 
we found a more homoscedastic scatter. The CR within one hour of each 
parameter expressed as the percent change from the initial value was: IC, 
19%; FIV1, 14%; PIF, 18%; MEF50, 21%.
Conclusions:  To obtain a more homoscedastic scatter, percentage changes 
in FIV1, IC and MIF50 are more appropriate than absolute changes. 
In	 an	 individual	 patient	 with	 COPD,	 a	 significant	 improvement	 for	 a	
particular parameter must at least exceed the above-mentioned CR.  
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Background 
	The	severity	of	chronic	obstructive	pulmonary	disease	(COPD)	is	defined	
by	the	degree	of	expiratory	airflow	limitation.	It	is	essential	for	diagnosis	
and provides a useful description of the severity of pathological changes 
in COPD [1]. It is, however, well known that the correlation between the 
subjective improvements in dyspnea and the increases in Forced Expiratory 
Volume in 1 second (FEV1) after inhalation of bronchodilators is low [2-4]. 
Many	COPD	patients	do	not	show	significant	reversibility	of	FEV1	after	
bronchodilators,	as	defined	by	a	12%	improvement	from	the	initial	value	
and at least 200 ml [5], but may experience less dyspnea from their use. 
Taube and co-workers [4] demonstrated that this change in dyspnea 
may	be	 related	 to	 improvements	 in	 inspiratory	flow	 rates.	These	 authors	
found that in patients with severe COPD (FEV1 mean was 38% of the 
predicted normal value), the reduction in dyspnea after the inhalation of 
a beta (2)-adrenoreceptor agonist was closely correlated to the change in 
parameters of forced inspiration, particularly for the forced inspiratory 
volume in 1 second (FIV1), but not with changes in parameters of forced 
expiration.	They	also	concluded	that,	“In	less	severe	COPD	or	asthma,	the	
reduction in dyspnea was associated with the improvements in both FIV1 
and	FEV1,	but	in	severe	COPD	with	the	improvement	in	FIV1	only”	[6].
O’Donnell et al. found a correlation between the change of the Inspiratory 
Capacity (IC) after bronchodilator administration, dyspnea and duration 
of	 exercise	 [7,8].	 In	 2005,	 a	 published	 ATS/ERS	 statement	 on	 clinical	
pulmonary function testing [9] made no recommendations on the 
measurement of inspiratory parameters including FIV1 . Therefore, it is 
unclear how FIV1 and other inspiratory parameters should be measured 
and which improvements in a patient are beyond random variation for these 
parameters after the use of bronchodilators or other interventions. 
How FIV1 should be measured in patients with COPD was the subject of a 
previous study by our group. We found that the optimal FIV1 was obtained 
immediately after a slow expiration (in contrast to a forced expiration) and 
that	at	least	five	forced	inspiratory	maneuvers	should	be	performed	[10].
However, there is no clear consensus about how to express reversibility 
in	subjects	with	airflow	limitation	[5].	The	two	most	commonly	described	
methods are the percent change of the initial value and the absolute change 
in the parameter value. As the percent change from the initial value is too 
sensitive at very low values, as measured in severe obstructive patients, a 
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third method uses the percent change from the predicted normal value [5]. 
For the inspiratory parameters under study, no accepted predicted normal 
values	are	available;	hence,	we	used	the	first	two	methods.	
For	an	individual	patient	with	COPD,	a	significant	bronchodilator	response	
must at least exceed the random variation for the parameter of interest. 
Therefore, it is important to know which type of variation or scatter exists 
for that parameter. Figure 1 shows a theoretical dataset of a test-retest lung-
function parameter with different types of scatter. In the left panel, we 
made the amount of scatter the same for each value of the parameter, called 
“homoscedastic”	scatter.	For	the	whole	range	of	the	parameter,	we	can	use	
the same value for the random variation, and a difference of more than 0.2 
is beyond the random variation. 
Figure 1. Bland and Altman plots with theoretical types of scatter. The 
vertical axis shows the test (T) retest (R) difference (T-R); the horizontal axis 
shows the average (T+R/2). Each point corresponds with one test-retest pair. 
Left panel: dataset with a random scatter not dependent on the parameter 
value. 
Right panel: same dataset, but now the percent change from the average 
parameter value is shown; the scatter is highly dependent on the parameter 
value. In the left panel, the scatter can be described with just one value, e.g., 
the coefficient of repeatability (CR). In the right panel, the scatter cannot be 
precisely described with one value because the scatter on the low and high 
parameter values will not precisely reflect a fixed CR. Thus, for describing 
random variation, a homoscedastic scatter is preferred.
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The same dataset is used in the right panel, in which the differences are 
related to the (average) parameter value (percent difference) but now the 
amount of scatter depends on the parameter value: the higher the value, the 
less (in this example) scatter or random variation there is; this type of scatter 
is	called	“heteroscedastic”.	Therefore,	it	is	important	to	know	the	type	of	
scatter of the parameters in which we are interested. A more homoscedastic 
scatter is desired when we express the differences as absolute differences or 
as relative to the parameter value. 
The	first	topic	of	this	study	is	to	investigate	which	type	of	scatter	applies	to	the	
(absolute and percent) changes in inspiratory parameters (FIV1, Inspiratory 
Capacity (IC), Peak Inspiratory Flow (PIF) and Maximal Inspiratory Flow 
at	50%	(MIF50)).	Next,	we	determine	the	coefficient	of	repeatability	(CR)	
for the given parameters [5,11]. 
Methods 
A total of 79 (58 male) consecutive patients who met ATS-ERS [12] criteria 
for  COPD were recruited from our outpatient clinic. Criteria for inclusion 
were	a	patient	age	≥	40	years,	a	smoker	or	former	smoker	(≥10	pack	years),	
stable disease and an ability to perform lung function tests. Excluded 
patients were those on oral corticosteroids or antibiotics in the month before 
inclusion, or those who had symptomatic heart failure, respiratory diseases 
other than COPD, a history of asthma, allergic rhinitis or active cancer 
disease (except basal cell carcinoma of the skin). The study was approved 
by the Hospital Medical Ethical Committee, and all patients gave informed 
consent.
Patients were asked not to use short-term bronchodilators for the six to eight 
hours prior to the study and long-term bronchodilators for at least 12 hours 
before the study. Tiotropium and theophylline b.i.d. were not allowed to be 
used for the 24 hours prior to the spirometric test.
 Before the tests, a 3.00-liter calibration syringe was used at three different 
emptying	and	filling	speeds	to	check	linearity,	as	recommended	by	ATS	and	
ERS standards [9]. The ambient (room) temperature was measured before 
each	test	session	so	that	BTPS	corrections	on	the	flows	and	volumes	were	
adequately performed. 
Lung	function	tests	were	performed	five	times	on	the	first	day	(9,	10,	11,	
14 and 15 hours) and once at nine hours within the following two weeks. 
56
Chapter 4
Between the two days, the medication did not change. Also, on the second 
day the patients were requested to discontinue bronchodilators as on day 
one.	For	expiratory	parameters,	three	adequate	and	acceptable	flow	volume	
curves	were	produced	 in	accordance	with	conventional	ATS/ERS	criteria	
[9]. The largest forced vital capacity (FVC) and FEV1 were recorded. For 
the predicted FEV1 and FVC, the normal values of the European Respiratory 
Society were used [13]. 
For	 inspiratory	parameters,	five	adequate	 IC	measurements	 and	maximal	
forced inspirations after a slow and maximal expiration were obtained. Full 
inspiration	was	obtained	when	a	plateau	in	the	flow	was	reached	or	after	at	
least	an	eight-second	duration	of	the	inspiration.		Of	these	five	maneuvers,	
we took the highest value obtained for the FIV1, IC, PIF and MIF50 [10]. 
IC was measured by the method described by Hadcroft and Calverly [14] 
immediately before each forced inhalation.
If, during the inspiratory maneuvers, the vital capacity (VC) was reached 
before	the	FIV1,	then	FIV1=VC.	The	flow–volume	curves	were	measured	
with a V-MAX20 (Sensor Medics, ViaSys, Conshohocken, PA, USA).
In order to obtain proper inspiratory parameters after a slow expiration, 
we began the measurement during the slow expiration and stopped the 
procedure when the patient reached maximal inspiration; otherwise, the 
V-MAX20 software rejects the values obtained. 
Analysis  
The	 five	 intra-day	 lung	 function	 parameter	 data	were	 analyzed	with	 the	
repeated measures ANOVA and Bonferroni’s multiple comparison tests.
The type of scatter (homoscedastic or heteroscedastic) was determined as 
follows. The differences between each test and retest value pair versus the 
average value were plotted as described by Bland and Altman [11]. Negative 
differences were transformed to positive values by taking the absolute 
values of the differences. We applied linear regression of these transformed 
differences on the average value of the parameter. When there is a pure 
homoscedastic scatter, the regression line will be close to horizontal and the 
slope	will	not	significantly	differ	from	zero.	When	there	is	a	heteroscedastic	
scatter,	 the	 slope	 of	 the	 regression	 line	 will	 be	 significantly	 different	
from zero. For each parameter, scatter plots were made for both absolute 
differences and percentage differences from the average value. With linear 
regression,	we	tested	for	the	significances	of	the	slopes.	Instead	of	slopes,	
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we	present	standardized	slopes,	i.e.,	correlation	coefficients,	as	these	can	be	
compared across parameters and methods.
The	coefficient	of	repeatability	(CR),	as	established	within	one	hour,	intra-
day and inter-day, was determined by the method described by Bland and 
Altman [11]. The CR was determined as 1.64 times the standard deviation 
of the differences, represented as absolute values or as percentages of the 
average values. We performed a one-tailed test instead of a two-tailed test, 
as the interventions we were interested in were expected to improve a 
parameter; hence, we took 1.64 times SD instead of 1.96 X SD.  This use of 
a one-tailed test is analogous to the way in which lower limits of normals 
are	calculated	[13].	CR	was	used	instead	of	the	more	common	coefficient	
of variation (CV) because CV does not take into account the type of scatter 
that can be visualized by the scatter plots of Bland and Altman [11]
Results
Seventy-nine patients were included for day one (intra-day measurements), 
and 76 were measured again within the following two weeks. For two 
patients, we were unable to get an appointment within the two weeks, and 
in one there was an exacerbation. The baseline patient characteristics are 
summarized in Table 1.
The	 intra-day	mean	 and	 SD	 values	 did	 not	 differ	 significantly	 (repeated	
measures ANOVA) on different occasions that day (see Table 2). Therefore, 
we took three value pairs per parameter for each patient with a one-hour 
difference	(9–10,	10–11	and	14–15	hours)	for	determination	of	the	type	of	
scatter	and	the	one-hour	coefficient	of	repeatability.
The type of scatter for the inspiratory parameters FIV1, IC, PIF and 
MIF:
The scatter of differences in IC values versus average IC value on two 
occasions in-between one hour is shown in Figure 2, panel A.  The scatter 
becomes wider when the average IC increases. Panel B presents the 
same data, except that negative difference values are made positive and a 
linear	regression	line	is	added	to	the	figure.	The	regression	line	is	not	flat	
(P<0.0001), as it would be if the scatter was independent of the IC (Table 3)
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Table 1. Characteristics of the COPD patient group.
COPD= Chronic Obstructive Pulmonary Disease; BMI=Body Mass Index; 
FEV1=Forced Expiratory Flow in One second; GOLD= Global Initiative for 
Chronic Obstructive Lung Disease (stage 1,2,3 or 4) .
Table 2. Mean and (SD) values of lung function parameters on five 
occasions during the day
FEV1=Forced Expiratory Flow in one second; FIV1= Forced Inspiratory 
Flow in One second; IC- Inspiratory Capacity; MIF50= Maximal Inspiratory 
Flow at 50% ; PIF= peak Inspiratory Flow.
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On the other hand, when the difference in IC is expressed as a percentage of 
the average IC (Figure 2, panel C), an evenly distributed scatter can be seen 
along the whole range of the average IC. The slope of the linear regression 
line	is	now	nearly	flat	(Figure	2,	panel	D)	and	is	not	significantly	different	
from zero (Table 3). 
Table 3. Linear regression: standardized slopes (r) and P values; tests 
whether the slope is significantly different from zero.  N=237
FEV1=Forced Expiratory Flow in one second; FIV1= Forced Inspiratory 
Flow in One second; IC- Inspiratory Capacity; MIF50= Maximal Inspiratory 
Flow at 50% ; PIF= peak Inspiratory Flow. See also Figures 2 and 3 and the 
text for further explanation.
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Figure 2. Panel A: Bland–Altman plot showing the absolute difference of 
Inspiratory Capacity (IC) versus the average; it shows a heteroscedastic 
scatter of the IC. Panel B: Absolute difference of IC versus average IC plus 
linear regression; this panel shows a slope in the regression line. Panel C: 
Difference IC now presented as the percentage of the average value; this 
panel shows a homoscedastic scatter. Panel D: Percentage difference of IC 
versus average IC plus linear regression; this panel shows a flat slope of the 
regression line, not significantly different from zero. The dashed lines in panel 
B and D represent the confidence interval of the regression line.
The other parameters were investigated in the same way as the IC, and the 
results of the linear regression are presented in Table 3. To visualize the 
(more homoscedastic) spread, the scatter plots of the FIV1, IC, MIF50 and 
PIF expressed as percentage differences can be seen in Figure 3.
We	did	not	find	a	flat	regression	line	for	either	presentation	of	the	parameters	
(as differences in liters or as percentage differences of the average 
value);	however,	for	all	but	 the	PIF,	we	found	a	more	flat	regression	line	
corresponding to a lower (r) value when the percentage difference of the 
average	value	was	used	(less	significant	difference	from	zero,	as	can	be	seen	
in Table 3).
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Figure 3. Left panels show the scatter (absolute differences and regression 
lines for FIV1, MIF50 and PIF). Right panels show the percentage differences 
for the same parameters. The dashed lines represent the confidence intervals of 
the regression lines. All slopes of the regression lines are significantly deviated 
from flat (zero); however, apart from the PIF, the percentage differences show 
regression lines that are more flat (closer to a zero slope). FIV1= Forced 
Inspiratory Flow in One second; MIF50= Maximal Inspiratory Flow at 50% ; 
PIF= peak Inspiratory Flow
The random variability presented by the coefficient of repeatability
The	coefficients	of	repeatability	for	IC,	FIV1,	MIF50	and	PIF	are	graphically	
presented	as	Bland–Altman	plots	in	Figure	4,	panels	A–D.	The	spread	around	
no	difference	(solid	line)	can	be	seen,	and	the	coefficient	of	repeatability	is	
presented as the dotted lines ±1.64 × standard deviation. We can also see 
the relatively even spread around the solid line, which is an indication of a 
more homoscedastic spread. In patients with COPD, we found that the one-
hour	random	variabilities	expressed	as	the	coefficients	of	repeatability	(CR)	
for the lung function parameters are: IC: 19%, FIV1: 14%, PIF: 18% and 
MEF50: 21% (Table 4).
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Figure 4. Panels A–D show Bland–Altman plots of the percentage difference 
versus the average of the IC, FIV1, MIF50 and PIF. The coefficient of 
repeatability (CR) corresponds with the dotted lines; in panel A, e.g., the 
coefficient of repeatability takes the value = 18.9%, which is 1.64xSD.
IC- Inspiratory Capacity; FIV1= Forced Inspiratory Flow in One second; 
MIF50= Maximal Inspiratory Flow at 50% ; PIF= peak Inspiratory Flow; 
SD=standard deviation.
In	 the	 same	way	 as	 the	 one-hour	 coefficients	 of	 repeatability,	 the	 intra-
day	 coefficients	 of	 repeatability	 and	 the	 in-between	 day	 coefficients	 of	
repeatability are investigated.
The	 intra-day	 random	 variabilities	 expressed	 as	 the	 coefficients	 of	
repeatability (CR) for the lung function parameters are: IC, 21%; FIV1, 
18%;	PIF,	18%	or	0.90	l/;	and	MEF50,	21%	(Table	4).
The inter-day random variabilities expressed	 as	 the	 coefficients	 of	
repeatability (CR) for the lung function parameters are: IC: 23%, FIV1: 
14%, PIF: 18% and MEF50: 21% (Table 4).
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Table 4. Coefficients of repeatability (CR) retested after one hour 
(n=237), after five hours (n=79) and after 3-10 days (n-76) (in % from 
initial value/absolute value)
FEV1=Forced Expiratory Flow in one second; FIV1= Forced Inspiratory 
Flow in One second; IC- Inspiratory Capacity; MIF50= Maximal Inspiratory 
Flow at 50%  PIF= peak Inspiratory Flow.
Discussion
Type of scatter
This study has shown that within the same subject, differences in lung 
function parameters (IC, FIV1, MIF50 and PIF) before and after one hour 
can more appropriately be described when taken as the percentages of 
the initial values than as differences in the absolute values because of the 
more homoscedastic scatter. All measured parameters showed a scatter that 
was	 significantly	dependent	 on	 the	 average	parameter	 value	 	 and	 thus	 is	
heteroscedastic	if	we	present	the	differences	in	liters	or	L/sec.	On	the	other	
hand, if we represent the difference as the percentage of the average value 
(which	is	nearby	the	initial	value),	we	found	no	significant	dependence	on	
the parameter value for IC and less dependence on the values for the FIV1 
and MIF50. 
Several studies have addressed the variability of lung function parameters, 
especially	on	forced	expiration	[15-19],	but	used	the	variation	coefficient	
instead of the method described by Bland and Altman [11]. Therefore,  the 
type of spread was not investigated. In the ATS-ERS statement, the method 
of Bland and Altman is described as the preferred method for investigating 
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the random variation, and this method makes the type of spread visible 
[5,11].
The only exception is the PIF, which displays a slightly steeper slope when 
expressed as the percentage difference.
Random variability
The one-hour repeatability is by far the most important random variability 
because most interventions we are interested in, such as bronchodilator 
response, can be measured within one hour. Subjects must at least exceed 
this random variation before it can be decided that an improvement of an 
intervention	can	be	attributed	to	that	intervention.	We	did	not	find	any	CR	
for inspiratory parameters in the literature.
We decided to pool our patients’ data (with one-hour differences measured 
at three time-points a day per patient) to obtain more data points and, 
thus, more reliable results. This pooling was possible because we found 
no	 significant	 differences	 between	 the	 group	means	 and	 spreads	 and	 no	
significant	differences	of	the	parameters	between	the	measurements	between	
9 a.m. and 2 p.m. This result is in contrast with Calverley et al. [20] and van 
Noord	 et	 al.	 [21],	who	 found	 significantly	 lower	values	 at	 3	 and	6	 a.m.;	
however, we did not measure at these hours.
We	chose	the	CR	instead	of	the	more	popular	variation	coefficient	because	
it	 more	 precisely	 reflects	 the	 repeatability	 and	 provides	 a	 graphical	
representation of the type of scatter, as stated by Bland and Altman [11] and 
the recommendations of the ERS-ATS committee [5].
The CR for the PIF is less than that for the MIF50 which may be because the 
MIF50	is	situated	near	the	PIF	in	maximal	inspiratory	flow	volume	curves	
but is seldom exactly aligned; thus, the MIF50 demonstrated more spread.
Whether PIF improvement is therefore more sensitive to bronchodilators 
than MIF is not answered by this study.  
The	intra-day	coefficients	of	repeatability	are	important	to	know	when	we	
are performing interventions that take more than one hour, i.e., medications 
such as theophylline, tiotroprium or other interventions that take more time 
to retest.
We selected the 9-to-14-hour difference because all parameters as group 
means	did	not	change	during	this	interval.	There	was	a	small	but	significant	
decrease in some parameters (FEV1 and MIF50) on the 9-to-15-hour 
interval; therefore, we took the 9-to-14 as our difference. We think that this 
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decrease in some parameter values may be due to the fact that patients at 
the	end	become	tired	of	repeating	this	procedure	five	times	a	day,	during	
which time they were not allowed to take any bronchodilator drugs, or that 
there may be some circadian effect [20,21]. The higher intraday CR value, 
than  the  one hour CR value, could be expected because of the greater time 
interval. 
Improvements of interventions taking more than one day can be considered 
as	beyond	random	variation	when	the	inter-day	coefficients	of	repeatability	
are taken into account. Between the two days, patients did not change their 
medication and no exacerbations occurred. A weak point of these CR is 
that we were unable to see all patients on an exact inter-day interval of one 
week because we were dependent on when our patients were able to visit 
our outpatient department again. As the smallest interval was three days, 
and the greatest interval was eight days, the analyses were all conducted 
within two weeks. In general, the longer the interval between the two 
measurements (from one hour to several days), the greater the CR obtained. 
This	result	may	be	caused	by	the	longer	time	period	for	weather	to	influence	
the patients or other effects of irritants in the environment.
Similar to the one-hour and intra-day random variation, we were unable 
to	 find	 the	 inter-day	 random	 variation	 on	 inspiratory	 parameters	 in	 the	
literature. 
Limitations of this study
The subjects in this study include the investigation of only patients with 
COPD, so it does not extend to normal patients or those with asthma or 
restrictive disease. The random variation in these groups may be different.
The type of scatter was only examined after one hour, and it may be different 
when other intervals are taken into account.
The wash-out time for Tiotropium was 24 hours, although some investigators 
used 48 hours for this drug. We think this 24 hours time period had limited 
influence	on	the	test-retest	results.
We used all data including the outliers to construct the Bland and Altman 
plots;	 in	 small	 samples,	 this	 can	 influence	 the	 linear	 regression	 of	 the	
transformed Bland and Altman plots when the outliers are in the lower or 
upper zones of the average parameter value.
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Conclusions 
Differences in lung function parameters (IC, FIV1, MIF50 and PIF) are 
described with less dependence on the parameter values when taken as 
percentages from the initial values than as absolute difference values. 
The	random	variation	expressed	as	coefficients	of	repeatability	for	several	
time intervals are presented. 
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Abstract
Background: In patients with severe chronic obstructive pulmonary disease 
(COPD), pursed-lips breathing (PLB) improves the pulmonary gas exchange 
and	hyperinflation	measured	by	electro-optic	coupling.	The	response	to	PLB	
in inspiratory lung function tests is not known. Objectives: The purpose of 
this study was to measure the effect of PLB on inspiratory parameters. 
Methods:	Thirty-five	subjects	with	stable	COPD	and	a	forced	expiratory	
volume	 in	 first	 second	 (FEV1) <50% of the predicted value were tested 
for the following primary parameters before and immediately after PLB, 
and 5 min later: forced inspiratory vital capacity, inspiratory capacity (IC), 
forced	inspiratory	volume	in	first	second,	maximal	inspiratory	flow	at	50%	
of	VC,	and	peak	inspiratory	flow.	Patients	were	also	tested	for	the	following	
secondary parameters: vital capacity (VC), FEV1, breathing frequency (BF), 
end-tidal CO2 tension (ET-CO2), and oxygen saturation (SO2). 
Results: Of all the primary parameters only IC (p = 0.006) improved 
significantly;	with	regard	to	the	secondary	parameters,	the	mean	SO2 was 
improved by 1% (p = 0.005) and the mean ET-CO2 and BF decreased 
significantly	 (p	 <	 0.0001	 for	 both)	 to	 3.2	 mm	 Hg	 and	 3.1	 breaths/min,	
respectively. After 5 min the effects diminished. 
Conclusion:	Improved	IC	after	PLB	indicate	less	hyperinflation	in	patients	
with	severe	COPD;	there	was	no	effect	on	parameters	of	flow.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a preventable and 
treatable disease but is still the fourth leading cause of death in the world 
[1].	The	severity	of	COPD	is	defined	by	the	degree	of	expiratory	airflow	
limitation.	 Airflow	 obstruction	 is	 essential	 for	 diagnosis,	 and	 forced	
expiratory	volume	in	first	second	(FEV1)	provides	a	useful	description	of	
the severity of the pathological changes in COPD [1]. However, FEV1 is 
not very well correlated with changes in dyspnea. Inspiratory parameters 
may be more sensitive in relation to dyspnea as was published by Taube et 
al. [2]. They are also sensitive to bronchodilators in patients with COPD 
[2-4].
Pursed-lips breathing (PLB) is a breathing exercise and an item of patient 
education in rehabilitation programs [5, 6]. PLB may improve pulmonary 
gas exchange [7, 8] and reduce the breathing frequency (BF) and end-
expiratory volume measured by optoelectronic plethysmography, thereby 
decreasing	hyperinflation	[9,	10].	A	decrease	in	dyspnea	and	an	increase	in	
tidal volume are other consequences of PLB in patients with moderate-to-
severe COPD [6]. Additionally, a faster recovery from dyspnea and a slower 
respiratory rate were found after walking with PLB [11].
The physiologic changes induced by PLB cause an increased intrabronchial 
pressure during expiration and, as a consequence, may increase the bronchial 
diameter	and	thus	improve	the	inspiratory	and	expiratory	flow.	The	positive	
intrabronchial pressure prevents the collapse of the bronchi upon expiration 
and may therefore decrease the closing volume and improve the inspiratory 
capacity (IC) and vital capacity (VC).
We do not know how long this effect remains after PLB; however, we think 
it is maintained for approximately 5 min during quiet breathing (except 
when the patient performs a forced expiration). We wonder whether FEV1 
changes at all during PLB because of the compression due to a negative 
intrabronchial pressure causing airway collapse. We hypothesized that 
inspiratory parameters could be improved by PLB resulting in a decrease 
in dyspnea.
The aim of this study was to evaluate the effect of PLB in patients with 
severe-to-very-severe COPD (GOLD stages 3 and 4) on the following 
inspiratory	parameters:	forced	inspiratory	volume	in	first	second	(FIV1),	IC,	
maximal	inspiratory	flow	at	50%	of	VC	(MIF50),	and	peak	inspiratory	flow	
72
Chapter 5
(PIF); secondary outcome parameters included FEV1, forced VC (FVC), 
oxygen saturation, end-tidal CO2 tension (ET-CO2), BF, and dyspnea.
Methods
A total of 35 consecutive patients who met the GOLD criteria for COPD 
were recruited from our outpatient clinic. Inclusion criteria were: GOLD 
stages 3 and 4, reversibility of FEV1 <12% of the predicted normal value 
and	<200	ml,	age	≥40	years,	smoker	or	former	smoker	(≥10	pack-years),	and	
stable disease. Patients on oral corticosteroids or antibiotics in the month 
before inclusion and patients with symptomatic heart failure, respiratory 
diseases other than COPD, a history of asthma, allergic rhinitis, and active 
cancer (except basal cell carcinoma of the skin) or with spontaneous PLB 
were excluded. The study was approved by the hospital’s medical ethical 
committee and all patients gave their informed consent.
Study Design
Patients were asked not to use short-term bronchodilators 6 h prior to the 
study and long-term bronchodilators were stopped at least 12 h before the 
study. The use of tiotropium bromide and theophylline was not allowed 24 h 
prior to the spirometric test.
Patients were asked to rest and breathe quietly for at least 2 min before 
the start of the test, followed by the recording of basal values for BF, ET-
CO2, and oxygen saturation (SO2) as well as lung function tests for the 
inspiratory and expiratory parameters FIV1, IC, forced inspiratory vital 
capacity (FIVC), PIF, MIF50, and FEV1. 
After these measurements patients rested for 5 min and thereafter they 
learned the PLB procedure with the following instructions: ‘Sit straight and 
relax your neck and shoulders. Lean with your arms on the arm rests of your 
chair. Breathe quietly in through your nose and out by means of pursed lips. 
During the inspiration your mouth should be closed. The expiration should 
be about 2 times longer in duration than the inspiration’.
After these instructions the patient was asked to demonstrate the PLB 
procedure; if the procedure was not adequately performed, the assistant 
corrected the patient by instructing him on what to do until the correct 
procedure was learned by the patient.
The values during PLB were recorded as follows: the patient practiced 
PLB for 2 min followed by 1 inspiratory maneuver to obtain the inspiratory 
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parameters;	 this	 process	 was	 repeated	 until	 5	 adequate	 inspiratory	 flow	
curves	were	obtained	(fig.	1).	The	largest	FIV1,	IC,	FIVC,	PIF,	and	MIF50	
were recorded. Responses to the visual analog scale (VAS), as well as SO2, 
ET-CO2, and BF were recorded just before the 5th inspiratory maneuver
Figure 1. Method of measurement of the lungfunction parameters.
Two minutes of PLB is followed by one forced inspiratory maneuver this is 
repeated until 5 inspiratory maneuvers are obtained, 3 forced expiratory 
maneuvers are obtained after another 2 min. of PLB. Insp.=inspiratory 
min=minutes, Exp.=expiratory.
Thereafter, the patient practiced PLB for 2 min followed by the expiratory 
maneuver to obtain the expiratory parameters. This process was repeated 
until	3	adequate	expiratory	flow	curves	were	obtained.	The	largest	FEV1	
and FVC were recorded. Five minutes after the last measurement the same 
parameters were recorded along with the responses to the VAS in order to 
obtain the post-PLB values.
Pulmonary Function Tests
Lung function was measured both at forced expiration and inspiration as 
follows: a 3-liter calibration syringe was used at 3 different emptying and 
filling	 speeds	 to	 check	 linearity,	 as	 recommended	by	American	Thoracic	
Society (ATS) and European Respiratory Society (ERS) standards. The 
ambient (room) temperature was measured before each test session to allow 
body temperature, pressure, and saturation corrections to be applied to the 
flows	and	volumes.
To measure the basal and post-PLB values of FVC and FEV1, patients 
performed as many maneuvers as needed (with a maximum of 8) to achieve 
3	adequate	and	acceptable	flow-volume	curves,	according	to	conventional	
ATS/ERS	criteria.	
For inspiratory parameters, 5 maximal forced inspirations after a slow and 
maximal expiration were obtained. Maximal inspiration was obtained when 
a plateau was reached or after at least 8 s of inspiration.
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In order to obtain proper inspiratory parameters after a slow expiration, we 
started the measurement during slow expiration and stopped the procedure 
when the patient reached FIVC, as otherwise the software of the V-MAX20 
spirometer (SensorMedics, ViaSys, Conshohocken, Pa., USA) would reject 
the obtained values.
If during the inspiratory maneuvrs VC was reached before FIV1, then FIV1 
= VC. The largest FVC, FEV1, and FIV1 were recorded. For the predicted 
FEV1 and FVC, the normal values of the European Community for Steel 
and Coal were used [12].
The	 flow-volume	 curves	 were	 measured	 with	 a	 V-MAX20	 spirometer	
(Sensor Medics). ET-CO2 was recorded with a Nellcor N1000 oximeter 
(Nellcor Puritan Bennett, Inc., Pleasanton, Calif., USA). SO2 was recorded 
with a Nellcor NPB40 pulse oximeter (Nellcor Puritan Bennett) 
Visual Analog Scale
The	patients	were	asked	to	fill	out	a	VAS	[2,	13].	On	the	10-cm	long	VAS	
scale the middle represents no change, and the left and right edges of the 
line represent the most dyspnea and least dyspnea, respectively. 
Statistics
The differences between inspiratory and expiratory parameter values before 
and after PLB were calculated with a 2-tailed paired Student t test. p < 0.05 
was	defined	as	a	 statistically	 significant	difference.	Correlations	with	 the	
VAS scale (Spearman’s rank correlation test) were determined. VAS scores 
are	 presented	 as	means	 and	 confidence	 intervals	 (CI)	 of	 the	means.	The	
D’Agostino-Pearson omnibus normality test was used to check whether the 
distribution of the VAS scores was normal. For statistical calculations we 
used GraphPad Prism5 for Windows (www.graphpad.com).
Results
Of the 35 patients in the study, 2 were not able to learn the PLB procedure 
and 1 was not able to perform the inspiratory lung function maneuver. 
Therefore,	 32	 patients	 were	 eligible	 for	 analysis.	 Twenty-five	 patients	
had GOLD stage 3 and 7 had GOLD stage 4 COPD. The clinical and 
demographic characteristics are summarized in table 1.
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Differences in inspiratory parameters before 
and 5 minutes after Pursed Lip Breathing
Table 1 Clinical and demographic characteristics
                                                                                        Mean (SD)
Change in Inspiratory Parameters during PLB and 5 min Later. 
During	 PLB,	 we	 found	 a	 significant	 improvement	 in	 IC	 with	 a	 mean	
increase of 89 ml (range --190 to +570); 6 patients had an increase of 200 
ml	or	more.	MIF50	showed	a	significant	mean	decrease	of	170	ml/min.	
The	other	parameters	were	not	significantly	altered	by	PLB.	
Five	minutes	later,	none	of	the	inspiratory	parameters	showed	any	significant	
improvement in relation to the basal values (before PLB). The IC was still 
61 ml higher than at baseline but a 2-tailed paired t test showed that this 
difference	lacked	significance	(p	=	0.061).	When	we	compared	the	changes	
in parameters during PLB and 5 min after PLB, we found a mean change 
in	IC	of	28	ml	(p	=	0.237,	not	significant).	The	results	are	summarized	in	
table 2. 
Table 2 
Differences in inspiratory parameters
before and during Pursed Lip Breathing
 
P vaulue < 0.001 (extremely significant) is summarised with ***;  P value 0.001 
to 0.01 (very significant) summerised with ** and 0.01 to 0.05 (significant) 
summarised with *
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Differences in secondary parameters before 
and 5 minutes after Pursed Lip Breathing
Change in Secondary Parameters during and 5 min after PLB.
Expiratory	lung	function	parameters	FEV1	and	FVC	did	not	show	significant	
differences (mean changes in differences -11 and +59 ml, respectively). 
However,	SO2,	end-tidal	pCO2,	and	BF	all	 showed	small	but	 significant	
improvements during PLB. 
Five minutes after PLB the improvements diminished somewhat, except 
in	 FVC	which	 showed	 a	 significant	 improvement	 compared	 to	 the	 basal	
value (mean change in differences 105 ml; p = 0.009); however, there was 
no	significant	improvement	compared	to	the	value	immediately	after	PLB	
(mean change in differences 46 ml; p = 0.143). The results are summarized 
in table 3.
Table 3 
Differences in secondary parameters 
before and during Pursed Lip Breathing
P vaulue < 0.001 (extremely significant) is summarised with ***;  P value 0.001 
to 0.01 (very significant) summerised with ** and 0.01 to 0.05 (significant) 
summarised with *
Correlations between the Dyspnea Score and Improving Parameters 
with PLB.
We	 correlated	 those	 parameters	 that	 showed	 significant	 improvements	
during or after PLB with the subjective change in the patients’ feelings of 
dyspnea.	None	of	the	parameters	showed	a	significant	correlation	with	the	
patients’ feelings of dyspnea. Only SO2 showed a tendency to correlate 
weakly	with	the	VAS	score	(--0.038,	p	=	0.08,	not	significant).	The	results	
are summarized in table 4.
77
Pursed lip breathing improves inspiratory capacity in COPD
 5
Table 4 Correlations between dyspnea (VAS) and change in parameter values 
VAS Score Immediately after PLB and 5 min after PLB.
Patients recorded an improvement on the VAS scale immediately after PLB 
with a mean of 7.8 mm (CI 3.3-12.2) out of 50 mm. Patients recorded an 
improvement on the VAS scale 5 min after PLB with a mean of 7.6 mm (CI 
2.6-12.5) out of 50 mm. The distribution of the VAS scores was normal. 
Discussion
Change in Inspiratory Parameters Immediately after PLB
We	 found	 a	 significant	 improvement	 in	 IC	 following	 PLB.	 However,	 9	
patients showed a decrease in IC ranging from 10 to 190 ml; 4 of them had 
a decrease of more than 100 ml. 
To our knowledge, no data exist on inspiratory pulmonary function tests 
after PLB in the literature, but of all the inspiratory parameters measured 
(FIV1, IC, MIF50 and PIF) only IC showed improvement. IC is a static lung 
function	parameter	that	is	also	a	marker	of	hyperinflation.	Optoelectronic	
plethysmography	(OEP)	showed	a	significant	reduction	(mean	±	SD)	in	the	
end-expiratory volume of the chest wall [9] during PLB (-0.33 ± 0.24 liters; 
p	<	0.000004).	This	finding	of	a	lower	end-expiratory	volume	by	OEP	is	
supported	by	our	finding	of	an	increase	in	IC	after	PLB.	However	the	change	
in OEP volume of 0.33 liters was higher than our mean change of 0.098 
liters. This difference may be partly attributed to patient selection, as we 
only included GOLD stages 3 and 4, and to the other types of measurements 
that were performed (change in chest wall dimensions). Our study also 
supports	reduced	hyperinflation	(improved	IC)	following	PLB	as	reported	
78
Chapter 5
previously.	 This	 reduction	 in	 hyperinflation	may	 also	 be	 responsible	 for	
the improved oxygen cost of breathing [14] and the faster recovery after 
walking [15]. 
MIF50	showed	a	significant	mean	decrease	of	170	ml/s	(p	=	0.049).	This	
change in MIF50 was the opposite of what we expected. We speculate that 
this	effect	may	be	caused	by	reflex	bronchoconstriction	(a	stretching	of	the	
J receptor in the bronchial wall caused by higher intrabronchial pressure 
during PLB).All other parameters of dynamic (forced) lung function were 
not	significantly	changed	after	PLB.	
Change in Inspiratory Parameters 5 min after PLB
All	 inspiratory	 lung	 function	 parameters	 lacked	 significant	 improvement	
after 5 min in relation to the basal values (before PLB). The IC was still 
61 ml higher than at baseline but a 2-tailed paired t test showed that this 
difference	lacked	significance	(p	=	0.061);	when	we	compared	this	value	to	
the	IC	during	PLB	we	found	no	significant	decrease	either.	Thus,	after	5	min	
some of the initial improvement in IC had disappeared. We did not take any 
measurements later to see how long the improvement due to PLB lasted, nor 
did	we	find	any	clues	in	the	literature	to	answer	that	question.
Change in Secondary Parameters Immediately after PLB
Expiratory lung function parameters like FEV1 and FVC did not show 
change after PLB. No studies are available on this subject; therefore, we are 
not able to compare our results with those of others.
In contrast to FEV1 and FVC, SO2, end-tidal pCO2, and BF showed small 
but	 significant	 improvements	 similar	 to	 those	 reported	 previously	 [16].	
The reason for a better SO2 may be a lower cost of oxygen due to less 
hyperinflation	 (less	 work	 breathing).	 Less	 hyperinflation	 improves	 lung	
compliance which may be the explanation for the decrease in BF.
Change in Secondary Parameters 5 min after PLB
Five minutes after PLB the improvements in BF, end-tidal pCO2, and 
SO2 diminished again. FVC, however, improved compared to the basal 
value.	This	 improvement	in	FVC	surprised	us,	but	might	also	reflect	 less	
hyperinflation.	Why	this	change	reached	significance	after	5	min	and	not	
immediately after PLB is a question we cannot answer. As stated earlier, we 
did	not	find	any	data	on	these	parameters	in	the	literature.
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Dyspnea and Correlations with Changes in Parameter Values. 
We found a mean difference of 4.85 ml in the VAS score after test-retest, 
which	 was	 significantly	 less	 than	 the	 7.75ml	 mean	 difference	 found	
immediately after PLB (Mann-Whitney test; p < 0.001). This is compatible 
to the improvement in dyspnea that we found in the literature [6, 16]. 
However,	 no	 significant	 correlations	 were	 found	 between	 significantly	
changed parameters after PLB and the feeling of change in dyspnea 
recorded by the patients. Furthermore, as this study was underpowered to 
find	significant	changes,	very	weak	correlations	remained;	thus,	we	do	not	
know which of the parameters contributed to a reduced feeling of dyspnea 
in patients after PLB. This issue was reviewed by Dechman and Wilson [16] 
and they found only 1 article, by Ingram et al. [17], which suggested that 
the higher collapsibility of bronchial airways in responders compared with 
nonresponders could be responsible. 
Spahija	et	al.	[18]	found	a	strong	and	significant	association	between	change	
in the end-expiratory lung volume and the VAS score during exercise. 
However, they only tested 8 patients with COPD, 6 of whom had an FEV1 
<50% of the predicted value. From their data, we calculated the association 
between the change in IC and the change in the VAS score and we also 
found	a	significant	association;	however,	when	we	omitted	patient	7	of	their	
data (because this case had an outlying change in the dyspnea VAS score 
compared	with	the	other	7	subjects),	 the	significant	association	vanished.	
We think that much more data of patients with severe COPD are needed in 
order to obtain robust results. The VAS dyspnea did not change before or 
after PLB at rest (which is in line with what we found). Their method of 
VAS measurement was different; they used an absolute VAS scale (0-10) 
2 times and we used a VAS scale 1 time to express the difference (less or 
more dyspnea).
Bianchi et al. [10] asked 30 patients with stable COPD to perform PLB at 
rest and found, in 19 patients, a reduction in the end-expiratory volume of 
the	chest	wall	(VeeCW),	corresponding	with	less	hyperinflation	after	PLB	
and an increase in tidal volume. Overall, he found an association between 
a	decrease	in	VeeCW	and	a	change	in	the	BORG	scale.	We	did	not	find	this	
association, but we used a VAS scale and not a BORG scale, and while 
we	measured	IC	via	spirometry	they	used	OEP.	Patients	who	hyperinflated	
during PLB had better FEV1 as a percentage of the predicted values (FEV1 
%pred) in their basal values. In the 4 patients with a decrease in IC of more 
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than 100 ml during PLB we found a mean FEV1 %pred of 42% compared 
with 37% in the whole group; we also found a mean change of 8.2 mm in 
their VAS dyspnea scores (range 0--20) compared with 7.8 mm in the whole 
group. 
In another study Bianchi et al. [9] analyzed 22 patients with COPD and 
found	that	the	patients	with	a	greater	reduction	in	hyperinflation	were	the	
patients with more severe airway obstruction. He also described a longer 
breathing cycle after PLB (hence a lower BF). We also found a lower BF 
after PLB but this was not associated with less dyspnea in our sample of 
COPD patients. 
In	our	study	10	patients	with	a	decrease	of	5	or	more	breaths/min	in	their	
BF had a mean change in VAS score of 9.3 mm compared with 7.8 mm for 
the whole sample. Bianchi et al. used OEP and a Borg scale in their study. 
Despite the fact that we were unable to associate less dyspnea with less 
hyperinflation	at	rest,	Bianchi	et	al.	found	this	association	in	their	sample	
of patients and Spahija et al. found an association between PLB and less 
dyspnea during exercise but not at rest. We think a larger sample of severe 
COPD patients is needed to clarify the association between PLB and the 
decrease in dyspnea. 
Conclusions
This study showed that there was an improvement in IC after PLB, 
supporting	 the	 idea	 of	 a	 decreased	hyperinflation	 in	 patients	with	 severe	
COPD and a possibly higher collapsibility of the bronchial airways. SO2, 
end-tidal pCO2, and BF also improved. We were not able to correlate these 
changes with a decreased VAS dyspnea score, however.
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Abstract
Background: The responsiveness of short-term bronchodilators on 
inspiratory lung function parameters (ILP), Forced Inspiratory Volume 
in one second (FIV1), Inspiratory Capacity (IC), Forced Inspiratory Flow 
at 50% of the vital capacity (FIF50), Peak Inspiratory Flow (PIF) and the 
relationship with dyspnoea in COPD subjects is sparsely examined. The 
aim of this study was to assess the effects of inhaled salbutamol 400 mcg, 
ipratropium 80 mcg and placebo on ILP and FEV1, and their relation with 
Visual Analogue Scale (VAS).
Methods: 85 subjects with stable COPD participated in a cross-over, 
randomized, double-blind placebo-controlled study. Spirometry was 
performed before and after inhalation of salbutamol, ipratropium and 
placebo. Changes in dyspnoea were measured with VAS. Primary analysis 
was done using 63 participants with absent reversibility. 
Results: all ILP and FEV1	improved	significantly	on	bronchodilators	except	
FIF50 after Ipratropium. After both bronchodilators, percent changes from 
initial values in IC were higher than corresponding changes in FEV1, but the 
differences	were	not	significant	(all	p>0.06).
Mean	 VAS	 score	 after	 bronchodilators	 and	 placebo	 showed	 significant	
improvements	 but	 did	 not	 significantly	 correlate	 with	 changes	 in	 lung	
function parameters. For each lung function parameter patients were further 
classified	 as	 responder	 or	 non-responder	 according	 to	 the	 degree	 of	 the	
change	from	baseline.	Response	rates	did	not	significantly	differ	between	the	
various	ILP.	Also	no	significant	differences	were	found	between	responders	
and non- responders regarding dyspnoea after bronchodilators. This applied 
to all ILP as well as to FEV1. 
Conclusions: In subjects with COPD, all ILP and FEV1 showed, just 
like	 the	 VAS	 score,	 significant	 improvements	 after	 bronchodilators.	
However ILP were not more sensitive than FEV1 for detecting responders 
on bronchodilators and for changes in the VAS score.
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Introduction
In Chronic Obstructive Pulmonary Disease (COPD) patients chronic 
inflammatory	 reaction	 and	 structural	 changes	 in	 central	 and	 peripheral	
airways and lung parenchyma are assumed to result in loss of elasticity 
of the airways leading to expiratory peripheral airway collapse, expiratory 
airflow	limitation	and	hyperinflation	[1,2].	Airway	obstruction	is	worldwide	
measured with Forced Expiratory Volume in one second (FEV1) and vital 
capacity (VC) ratio < 5 th percentile of predicted [3]. 	COPD	is	defined	by	
FEV1 /FVC	<70%	after	the	inhalation	of	short-acting	bronchodilator	[2].	In	
COPD patients FEV1 has a poor relationship with dyspnoea and is used, as 
a diagnostic tool for evaluation of bronchodilator therapeutic response and 
for	spirometric	classification	of	COPD	severity	[4-8].	FEV1 is often used 
because of its simplicity in performance, its known random variation and its 
well established reference values. There is a lack of correlation between the 
FEV1 and dyspnoea score in general and a low correlation between changes 
in FEV1 and changes in dyspnoea score after bronchodilation. O’Donnell 
et al., found a correlation between the change of the Inspiratory Capacity 
(IC) and dyspnoea after bronchodilator and during exercise [9-11] Taube et 
al. found in stable COPD at rest better correlations between the inspiratory 
lung function parameter  Forced Inspiratory Volume in one second  (FIV1)
and dyspnoea measured with Visual Analogue Scale (VAS) than with the 
expiratory lung function parameter FEV1 and dyspnoea [12].
We studied before the method of measurement of the FIV1 and random 
variation of inspiratory lung function parameters (ILP). Responders were 
defined	as	subjects	who	must	exceed	the	random	variation	[13].
Our hypothesis was that in COPD patients after inhalation of short-acting 
bronchodilators	 we	 would	 find	 more	 responders	 with	 inspiratory	 lung	
function parameters FIV1, IC, Forced Inspiratory Flow at 50% of the 
vital capacity (FIF50) and Peak Inspiratory Flow (PIF) than with FEV1. 
Additionally	we	aimed	to	confirm	the	findings	of	Taube	et	al,	who	found	a	
strong correlation between percentage change in FIV1 and improvement of 
dyspnoea after bronchodilators.
The aim of our study was to investigate if the effect of short-acting 
bronchodilators on ILP was higher compared with FEV1, on the number 
of responders and to investigate changes of these parameters for their 
correlation with dyspnoea scores. 
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Methods
Patients
Eighty-five	stable	COPD	patients	of	the	pulmonary	outpatient	clinic	of	the	
Canisius Wilhelmina hospital in Nijmegen, the Netherlands, were enrolled 
in this study performed in 2007 and 2008. The subjects had mild to very 
severe COPD (based on post-bronchodilator FEV1) according to the GOLD 
guidelines [1]. Inclusion criteria were stable COPD, age between 40 and 80 
years, current or former smoker with more than 10 pack-years and absent 
reversibility (an increase in FEV1  that is both greater than 200 ml and 12% 
above the pre-bronchodilator FEV1, according to historical records less 
than one year old) after short acting bronchodilators [3]. Stable COPD was 
defined	as	absence	of	exacerbations,	no	changes	in	COPD	medications	in	
the last 8 weeks, no use of oral corticosteroids in the last 2 months and no 
use of antibiotics in the last month. Also excluded were patients on oxygen, 
patients with allergic rhinitis or asthma, heart disease, neuromuscular 
disorders, malignancy or inability to answer questionnaires.
Study design
A double-blind, randomized placebo-controlled cross-over study was 
conducted. The randomization was performed by means of a computer 
generated list. The same subjects participated on three different days of the 
study, performing spirometric tests with reversibility testing on salbutamol, 
ipratropium or placebo. In a random order they were measured within a 
period of 2 weeks, received 4 puffs of 100 mcg salbutamol, ipratropium 
bromide 4 puffs of  20 mcg or 4 puffs of a placebo aerosol all with an 
Aerochamber plus. On these days standardized spirometry tests were 
performed before and after 30 minutes of the inhalation. 
Pulmonary Function Testing
All subjects were asked not to use short-term bronchodilators 6 hours prior 
to the study and long-term bronchodilators at least 12 hour before the study. 
Tiotropium and theophylline were not allowed to use 24 hours prior to 
spirometric test.
Expiratory spirometry measurements were performed using standard 
techniques according to ERS and ATS guidelines [14,15]. The largest 
Forced Vital Capacity (FVC) and FEV1 were recorded.  
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Figure 1 shows a normal spirogram and a flow-volume curve.
For the predicted FEV1 and FVC the normal values of the European 
Respiratory Society were used (Quanjer and Tammeling, 1993).  For ILP, 
maximal	inspiratory	flow	was	performed	after	slow	and	maximal	expiration	
and	at	least	five	adequate	manoeuvres	were	obtained	(Visser	et	al.,	2008)	
[13]. The best of the derived inspiratory parameters were further analyzed. 
Tests were performed with the patient in a seated position wearing a nose 
clip.	Full	inspiration	was	obtained	when	a	plateau	in	the	flow	was	reached	
or after at least 8 second duration of the inspiration. If during the inspiratory 
manoeuvres the VC was reached before FIV1, then FIV1 was considered 
to be equal to the FIVC. The largest FVC, FEV1, Forced Inspiratory Vital 
Capacity (FIVC) and FIV1 were recorded. For the predicted FEV1 and FVC 
the normal values of the European Community for Steel and Coal were 
used [16]. IC was measured with the method described by Hadcroft et al. 
[17].	The	flow-volume	curves	were	measured	with	the	V-MAX20	(Sensor	
Medics, ViaSys, and Conshohocken, PA, USA). For the three different 
measurements we used the same device and the measurements were 
performed by the same person at the same time of the day. 
In order to obtain proper inspiratory parameters after a slow expiration we 
started the measurement during slow expiration and stopped the procedure 
when the patient reached FIVC, otherwise the software of the V-MAX20 
rejects the obtained values [13].  The differences in FEV1 and the ILP values 
(FIV1 or FIVC, IC, FIF50 and PIF) after bronchodilatation were expressed 
both as changes in litres and as percent changes from initial value. 
We	defined	a	 significant	 improvement	within	a	 subject	 (responder)	as	an	
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improvement	of	more	than	the	Coefficient	of	Repeatability	(CR).	The	one	
hour CR of the lung function parameters from initial value were for FEV1 
12 %, FIV1 14 %, IC 19%, FIF50 21 % and PIF 18 % [18]. The CR within 
one hour, intraday and interday, was determined by the method described 
by Bland and Altman [19]. The CR was determined as 1.64 times the 
standard deviation of the differences represented as absolute values or as 
percentage of the average values. We performed this one-tailed test instead 
of the two tailed test described because interventions we are interested in, 
should improve that parameter. Therefore we took 1.64 times SD instead of 
1.96 times SD.  This is analogue the way in which lower limits of normal 
are calculated[16]. CR was calculated instead of the more commonly used 
Coefficient	of	Variation	(CV)		because	CV	does	not	take	into	account	the	
type of scatter that can be visualized by the scatter plots of Bland  and 
Altman.
Prior to the test all subjects were instructed on the use of the VAS. Dyspnoea 
score with a VAS was taken 30 minutes after bronchodilator administration 
[20]. The VAS line is a 10 cm long horizontal line and analyzed ranges 
from -5 to + 5 cm. On the left side the label represents VAS= -5 (very much 
improved), in the middle representing VAS=0 (no change) and at the right 
end VAS = +5 (much worsened). 
The medical ethical commission gave permission for this study and all 
patients gave written informed consent.
Statistical Analysis
All results are presented as mean value ± SD or indicated otherwise. Student’s 
t- test for paired data was used to compare the changes in parameters after 
bronchodilators or placebo. 
The one-sample t-test was used to compare mean changes with zero. 
Correlations between the change in VAS score and changes of lung function 
parameters after administration of bronchodilator and placebo were assessed 
with Spearman’s rho test. SPSS for Windows, version 15, was used for 
analysis and p-values < 0.05 (two-sided) were considered statistically 
significant.	Mann-Whitney	 test	was	 used	 to	 test	 the	 differences	 between	
responders and non-responders regarding distribution of VAS for ILP after 
bronchodilators.
All data were primarily analysed in the group of patients who were found 
to be non-reversible. An analysis for the whole group of included patients 
was also done.
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Results
Eighty-five	COPD	patients	consented	 to	participate	 in	our	study	and	had	
absent reversibility according to our patient records. Eighty-two of these 
patients completed the study. After completion of the study and unblinding 
the study medication at the analysis phase we discovered that a substantial 
fraction of the patients had a larger FEV1 responsiveness than expected. 
It turned out that 19 patients had an FEV1 increase	≥	10%	of	the	predicted	
value	after	the	use	of	salbutamol	and/	or	after	ipratropium.
For the primary analysis these 19 patients were excluded and the remaining 
63 patients were analyzed. Patient’s demographics and baseline pulmonary 
function of the 63 patients are presented in Table 1. These patients represent 
all four COPD GOLD classes. 
Table 1. Patient characteristics and baseline lung function 
parameters in 63 subjects
Definition of abbreviations:FEV1 = forced expiratory volume in 1 s, 
FIV1 = forced inspiratory volume in 1 s, IC = inspiratory capacity, 
FIF50	=	forced	inspiratory	flow	at	50%	of	the	vital	capacity,	PIF=	peak	
inspiratory	flow.	Values	are	given	as	mean	±	SD.	Baseline	values	were	
calculated as mean values of measured values at the three study days. 
GOLD = Global Initiative for Chronic Obstructive Lung Disease
90
Chapter 6
Changes in litres and percent changes from initial values in lung function 
parameters after bronchodilators
Changes	in	litres	(or	L/s)	and	percent	changes	from	initial	values	in	lung	
function parameters and VAS scores after treatments are presented in Table 
2. For salbutamol the range of changes (minimum-maximum) in FIV1, 
FIF50 and PIF with FEV1 was between 26 ml and approximately 229 ml. 
Ipratropium showed similar results with changes in litres ranging from 30 ml 
to 129 ml. From placebo the range of changes in ILP with FEV1 was between 
19	ml	and	112	ml.	All	increases	in	litres	(or	L/s)	after	bronchodilators	were	
significant	(p	<	0.01),	except	for	changes	in	FIF50 after Ipratropium which 
was	not	significant	(p	=	0.12).	Changes	in	litres	or	L/s	after	placebo	were	not	
significant	except	small	decreases	for	IC	(p	=	0.03)	and	FIF50 (p = 0.047).
The percent changes from initial value in FEV1 after bronchodilators and 
changes	 in	 the	 inspiratory	parameters	were	all	 significantly	 (all	p<0.008)	
different from zero except for FIF50 after ipratropium (p= 0.06). Percent 
changes	after	placebo	for	all	lung	function	parameters	were	not	significant	
(all p > 0.16).
Mean	VAS	score	after	both	bronchodilators	and	placebo	showed	significant	
improvements	(all	p	<	0.001)	but	did	not	significantly	differ	between	each	
other (all p>0.09). 
No	statistically	significant	correlations	were	found	between	GOLD	stages	
and	 changes	 in	 litres	 (or	 L/s)	 or	 relative	 changes	 of	 the	 ILP	 after	 both	
bronchodilators and placebo.
Relationships between changes in lung function parameters and dyspnoea 
(VAS scores) after bronchodilators or placebo
The relationships between VAS score and percent changes from initial 
values in FEV1, FIV1, IC, FIF50 and PIF after 30 minutes salbutamol and 
ipratropium is presented in Table 3.  
91
Reversibility of inspiratory lung function parameters 
 6
Table 2. Changes in litres (or L/s) and percent changes from initial value as 
compared  with baseline values at 30minutes after salbutamol, ipratropium 
or placebo and visual analogue scale (VAS) for dyspnoea, in 63 subjects with 
stable COPD. Values are expressed as mean ± SEM.
Definition of abbreviations:
FEV1 = forced expiratory volume in 1 s, FIV1 = forced inspiratory volume in 
1 s, IC = inspiratory capacity (L),
FIF50	=	forced	inspiratory	flow	at	50%	of	the	vital	capacity	(L/s),	PIF	=	peak	
inspiratory	flow	(L/s).	Changes	in	FEV1,	FIV1,	and	IC	are	given	in	litres	and	
FIF50	and	PIF	in	L/s.
For all lung function parameters percent changes from initial values 
were	 calculated	 as	 (post	 bronchodilator	 -pre	 bronchodilator/pre	
bronchodilator)*100%. 
*=	changes	after	ipratropium	or	placebo	which	are	not	significant.
VAS= Visual analogue scale is given in mean ± SEM. VAS scale ranges from 
-5 (very much improved dyspnoea) to VAS= +5 (much worsened dyspnoea) 
and VAS=0 represents no change.
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Table 3. Correlations of VAS score with lung function parameters 
changes after salbutamol and after ipratropium in 63 patients. Data 
shown are Spearman correlations with p-value
Definition of abbreviations: 
∆%	represents	=	percent	change	of	initial	value
VAS= Visual analogue scale
FEV1 = forced expiratory volume in 1 s
FIV1 = forced inspiratory volume in 1 s
IC = inspiratory capacity (L)
FIF50	=	forced	inspiratory	flow	at	50%	of	the	vital	capacity	(L/s)
PIF	=	peak	inspiratory	flow	(L/s)
No	statistically	significant	correlations	were	found	between	VAS	scores	
and the percent changes from initial value after bronchodilators for all 
lung function parameters, neither for salbutamol nor for ipratropium. 
Figure. 2 shows individual data for FEV1 and FIV1 changes versus VAS 
scores.
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For each lung function parameter (FEV1, FIV1, IC, FIF50 and PIF) patients 
were	classified	into	responders	or	non-	responders.	Responders	were	defined	
as subjects with a change greater than the one hour CR from initial value 
after bronchodilators. 
Using	 the	 Mann-Whitney	 test,	 no	 significant	 differences	 were	 found	
between responders and non- responders regarding the distributions of 
dyspnoea VAS scores for any of the lung function parameters, neither for 
salbutamol nor for ipratropium. These data are presented in Table 4. Neither 
for	ipratropium	nor	for	salbutamol	we	found	significant	differences	between	
the various lung function parameters with regard to response rates. 
Table 4. VAS scores according to whether or not the change from 
baseline was greater than the one hour coefficient repeatability of the 
various lung function parameters in 63 patients
Definition of abbreviations:
VAS= Visual analogue scale. VAS dyspnoea scores are given as mean ± 
SD.  VAS ranges from -5 to + 5. VAS =0 represents no change in dyspnoea, 
VAS<0= less dyspnoea and VAS >0= more dyspnoea.
*=	 one	 hour	 coefficient	 of	 repeatability	 of	 the	 particular	 	 lung	 function	
parameter 
FEV1 = forced expiratory volume in 1 s
FIV1 = forced inspiratory volume in 1 s
IC = inspiratory capacity (L)
FIF50	=	forced	inspiratory	flow	at	50%	of	the	vital	capacity	(L/s)
PIF	=	peak	inspiratory	flow	(L/s)
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Essentially the same conclusions held when all analyses were repeated for 
the	whole	group	of	eighty-five	included	patients.	The	same	applied	to	the	
subgroup of 51 patients of out of the whole group who met the stronger 
ATS/ERS	criteria	about	non-reversibility	[3]	.
Discussion
This study showed that all ILP as well as FEV1	have	statistical	significant	
improvements after short-acting bronchodilators in subjects with a stable 
COPD, except for FIF50 after ipratropium (Table 2). 
For both bronchodilators the percent changes from initial value in IC were 
different corresponding changes in FEV1.  For all the ILP, we found a small 
amount of responders after both bronchodilators and the response rates for 
both	bronchodilators	did	not	differ	significantly.	Response	rates	for	FEV1 
after both bronchodilators were also different corresponding response rates 
for ILP (Table 4).  
The criteria of reversibility after bronchodilator in COPD are very confusing 
and until 2005 there was no clear uniform international guideline for this. 
The number of COPD subjects participating in a study can strongly differ 
depending whether we use ERS criteria or ATS criteria and this knowledge 
makes	it	difficult	to	compare	similar	study	with	each	other	[21].
Most COPD studies use different criteria of reversibility in COPD like the 
ERS criteria of Siafakas et al as mentioned in 1995 with only change < 10 % 
of predicted value after short acting bronchodilator, or the ATS criteria from 
1994 and 2005 which prefer a change of > 12% of initial value and > 200 ml 
after short acting bronchodilator. With the ATS and ERS criteria from 2005 
which also prefer a change of > 12% of initial value and > 200 ml after short 
acting	bronchodilator,	we	can	define	reversibility	in	COPD	[3]	.
Most studies assessing acute effect on FEV1 in patients with COPD from short-
term bronchodilators, showed similar or larger response on anticholinergics 
compared to that on beta-2-agonists [22-24]. However, other studies have 
demonstrated equal effect with ipratropium and salbutamol. The reason 
for	a	higher	anticholinergic	response	could	be	increased	anticholinergic	–
mediated muscle tone and reduced mucus secretion  [25].
In our study we found that the mean VAS score after bronchodilators and 
placebo	showed	significant	 improvements,	but	did	not	significantly	differ	
between	each	other.	Our	study	could	not	confirm	the	results	of	 the	study	
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of Taube et al., in which with regard to the ILP, a strong correlation was 
found in changes in FIV1 and dyspnoea VAS score after administration of 
salbutamol. The lack of correlation in changes of VAS score after acute 
bronchodilation and the other lung function parameters in our study may be 
due to the fact that at least forty-four percent of our COPD subjects reached 
the FIVC within a second. This may cause the FIV1 to be less sensitive 
compared to the study of Taube et al[12]. 
Other	differences	between	the	study	of	Taube	and	our	study	might	be:	firstly,	
that our spirometric standard differs from his study. Unlike in our study, 
he used at least two measurements of forced inspiratory and expiratory 
volumes. Secondly, the population of his study, differs from that of our 
project. Our patients had probably a more stable COPD due to 
the inclusion criteria of the study. We included only subjects who did not 
have any exacerbation of their COPD within the last two months, did not 
use systematically corticosteroid or antibiotics in this period and none of 
our patient used (long-term) oxygen or theophylline. Thirdly, the population 
of both studies could have different severity of COPD subjects. In our 
population in 63 patients with COPD the FEV1 mean was 1.49 ± 0.73 litres, 
respectively 51 ±20 % predicted whereas in the study of Taube in 61 patients 
with COPD the FEV1 mean was  1.09 ± 0.49 litres, respectively FEV1: 38
 %; 
range: 13 to 80% predicted. This suggests that in his study the subjects had 
a more severe COPD. Furthermore his study is limited to the response on 
salbutamol and lacks the effect on anticholinergic drugs. Additionally, the 
perception of dyspnoea in subjects can be divided in less or more change in 
shortness of breath after bronchodilator, low-perceivers respectively high-
perceivers [26].  It is possible that in our study we had more low-perceivers. 
The question arises whether in subjects with stable COPD at rest and a lung 
function according to GOLD class I and II, relevant changes in dyspnoea 
after bronchodilators in a short period of 30 minutes may be expected. 
Noseda et al found a modest relationship (r = 0.51) between the change 
in VAS and FEV1	in	patients	with	COPD.	Other	studies	report	significant	
correlations with FEV1 and the baseline and transitional dyspnoea indices 
(BDI/TDI)	of	Mahler	 in	patients	with	COPD	 [27,28].	We	used	 the	 same	
VAS score as Taube but we found no results like in his study. The question 
arises if the relationship of changes in FEV1 and	dyspnoea	score	BDI/TDI	is	
better	than	with	VAS	score	and	what	the	relationship	between	ILP	and	BDI/
TDI will be. 
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In conclusion, short-acting bronchodilators in subjects with stable COPD 
showed	significant	improvements	in	both	FEV1 and ILP. ILP were not more 
sensitive than FEV1 for detecting responders on bronchodilators. We were 
not able to reproduce the high degree of correlations Taube et al. found 
between inspiratory parameters and VAS dyspnoea score.
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Abstract
Background: Pulmonary function testing is a key procedure in the work-up 
of patients who are suspected of having asthma and chronic obstructive 
lung disease (COPD). Therein, clinical visits and pulmonary function tests 
(PFTs)	are	the	major	contributors	to	the	overall	financial	costs.	
The	 aim	 of	 this	 study	 was	 to	 assess	 whether	 a	 specific	 diagnostic	 test	
protocol contributes to the optimization of the work-up of patients who are 
suspected of having asthma and COPD.
Methods: A prospective, single-blind, and randomized controlled study was 
performed. In the control group (CG), all of the PFTs that were ordered 
by the lung specialist were carried out. In the experimental group (EG), 
specific	 PFTs	were	 selected	 according	 to	 our	 protocol.	The	 primary	 end	
point	was	the	total	cost	of	achieving	a	final	diagnosis.	
Results: One hundred and seventy-nine patients were included into this 
study: 86 in the CG and 93 in the EG. The mean number of tests to diagnosis 
was 3.8 in the CG versus 2.9 in the EG (P<0.001). The mean number of 
redundant PFTs before diagnosis was 1.2 in the CG versus 0.08 in the EG 
(P<0.001). The number of patients who required an additional outpatient 
visit to complete diagnosis was higher in the CG in comparison to the EG 
(P=0.02). The mean cost of work-up per diagnosis was €227 in the CG 
versus €181 in the EG (P<0.001). 
Conclusions: In this group of patients with suspected obstructive lung 
disease, protocol-driven, PFT-based selection is more cost-effective than 
test selection at the discretion of lung physicians. 
Key words: COPD, asthma, cost-effectiveness, pulmonary function tests, 
diagnostics, redundant tests 
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Introduction
Diagnosing asthma and COPD is an important part of the daily practice of 
pulmonary physicians. Pulmonary function tests (PFTs) play a key role in 
the work-up of obstructive pulmonary diseases [1-3].
No	exact	figures	exist	for	the	annual	costs	that	are	associated	with	current	
diagnostic processes, although they are likely to be substantial. 
Finding the optimal diagnostic work-up in patients with obstructive lung 
disease is challenging. A physician who routinely orders most or all PFTs 
in the work-up of asthma and COPD patients, runs the risk of unnecessary 
testing; however, a physician who orders tests more sparingly, runs the risk 
of unnecessary outpatient visits. In view of the high incidence of patients 
with	obstructive	lung	diseases,	it	is	important	to	find	the	optimal	diagnostic	
work-up in each of these patients. To this end, we have developed a 
diagnostic protocol (Figure 1) that can be jointly used by physicians and 
pulmonary function assistants. In our group, some physicians already use 
this diagnostic PFT protocol; however, some of the physicians order PFTs 
without following the prescribed diagnostic PFT protocol.
Figure 1. Pulmonary function protocol for obstructive diseases. Criteria 
for obstruction, airway responsiveness (PC20 histamine), reversibility, and 
steroid tests (see text).
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Prior to the beginning of this study, there was no available evidence that 
demonstrated	 that	 protocol-driven	 PFT	 ordering	 is	 more	 efficient	 than	
physician-driven test ordering. Therein, we hypothesize that protocol-driven 
test	ordering	will	be	more	efficient	than	test	ordering	without	direction	from	
a diagnostic protocol.
The aim of this study was to assess whether protocol-driven test ordering 
reduces the number of redundant pulmonary function tests, decreases the 
number of outpatient visits, and increases the cost effectiveness of patient 
work-up in comparison to physician-driven test ordering. 
Methods 
A prospective, randomized, and single-blind trial was conducted at our 
outpatient unit.
An institutional review board (IRB) approved this study. This study was 
only	a	formal	stratification	of	the	current	practice;	hence,	informed	consent	
was not necessary. 
The study participants consisted of consecutive adult patients, who were 
referred to our respiratory outpatient clinic and suspected to have asthma 
or	COPD	at	 the	end	of	 the	first	outpatient	visit.	None	of	 the	patients	had	
recently (in the preceding three years) been diagnosed with asthma or COPD 
by a pulmonary physician. Patients were primarily referred by general 
practitioners; however, two patients referred themselves to our outdoor 
department, and three were referred by cardiologists. We excluded patients 
who were not able to adequately complete pulmonary function tests, were 
referred to a pulmonary physician because of an abnormal X-ray, needed 
pre-operative consultations, and have had an infection of the upper or lower 
airways or a possible exacerbation of obstructive airway disease in the past 
two months. 
In	the	first	visit,	the	physician	takes	a	medical	history,	performs	a	physical	
examination, makes a differential diagnosis, and orders laboratory testing, 
such as a chest X-ray. Only patients who were most likely to be diagnosed 
with asthma or COPD were included into this study. Physicians ordered 
diagnostic tests as they deemed appropriate and added the reason for the 
pulmonary function testing (e.g. suspected obstructive lung disease). At the 
end	of	the	first	outpatient	visit,	nurses	randomized	the	patients	into	the	control	
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group (work-up at the discretion of the physician) or the experimental group 
(work-up in accordance with the protocol) by pulling an opaque envelope.
PFT	 lab	 assistants	were	 notified	 of	 the	 outcome	of	 the	 randomization	 in	
order to allow them to perform investigations as ordered or per protocol.
The PFT protocol is shown in Figure 1. Therein, when the forced vital 
capacity (FVC) is less than normal, a total lung capacity (TLC) measurement 
was conducted in order to exclude restrictive lung disease. When the patients 
smoked more than 10 pack years, their respective diffusion capacities were 
measured.
A second physician independently examined the results for each patient and 
classified	the	patients	as	follows:
Completely reversible (CR): (1) An airway obstruction that is completely 
reversible	(FEV1	reversible	by	≥	9%	of	 the	predicted	value)	 to	a	normal	
range after beta-2 agonist and anticholinergic treatment; patients who 
received reversibility testing were tested for both bronchodilators; (2) An 
airway	obstruction	 that	 is	 completely	 reversible	 after	 14	 days	 of	 30	mg/
day of prednisone; and (3) normal PFTs but a decreased PC20 histamine 
threshold.
This PFT group supports to the diagnosis of asthma.
Non-reversible	obstructive	(NRO):	 Reduced	 FEV1	 and	 FEV1/FVC	
values,	which	are	 irreversible	after	beta-2	agonist	 and/or	anti-cholinergic	
treatment (an FEV1 increase of < 9% of the predicted value) and no return 
to	the	normal	range	after	10	days	of	30	mg/day	of	prednisone.	
This PFT group supports the diagnosis of COPD.
Partly	Reversible	Obstructive	(PRO):	Reversibility	is	present,	but	an	airflow	
limitation	persists.	FEV1	increases	by	≥	9%	of	the	predicted	normal	value	
but does not return to a normal range after bronchodilators. 
This	PFT	group	 supports	 the	diagnosis	of	 asthma	with	persistent	 airflow	
limitation or COPD with partly reversibility.
Normal	 PFT	group:	No	 airflow	 limitation	 and	 a	 normal	 PC20	 histamine	
threshold. 
This group does not support the diagnosis of obstructive lung disease; 
hence, a different diagnosis must be considered.
The second physician assessed if the appropriate tests were conducted 
according	 to	 the	diagnostic	flow	and	decided	on	 the	pulmonary	 function	
classification.	He	assessed	the	decision	about	the	final	diagnosis	of	the	PFT-
referring physician. 
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The	second	physician	calibrated	his	findings	with	the	findings	of	the	PFT	
ordering	physician	only	 if	 there	were	conflicting	findings.	 In	all	of	 these	
cases,	we	achieved	a	consensus	on	the	final	diagnosis.
COPD	and	asthma	were	finally	diagnosed	by	the	first	physician	on	the	basis	
of medical history (smoking behavior, allergies, a family history of asthma, 
and/or	a	pre-existing	childhood	condition);	PFTs	and	clinical	investigations,	
such as the eosinophil count; and the radioallergosorbent test (RAST).
In the protocol, the criteria for obstruction included an FEV1 < normal 
and	 an	 FEV1/FVC	 <	 normal	 according	 to	 Quanjer	 et	 al.	 [4].	 Airway	
hyperresponsiveness	 was	 defined	 as	 PC20	 histamine	 <	 4	 mg/ml	 [5].	
Reversibility	was	defined	as	a	≥9%	improvement	in	the	FEV1	in	comparison	
to	a	predicted	normal	value	[6-8].	Steroid	tests	consisted	of	30	mg/day	of	
prednisone for 10 days with the intent of reversing the FEV1 to normal 
levels, as advised by the Dutch Committee: diagnosis for asthma and COPD 
[7]. 
Forced vital capacity (FVC), forced expiratory volume in one second 
(FEV1), and airway responsiveness (PC20 Histamine) were measured 
according to ERS criteria [1]. 
During the follow-up visit, the results of all of the investigations that were 
carried out at the discretion of the physician or according to the protocol 
were	available	to	the	physician	who	then	decided	whether	a	final	diagnosis	
could be made. Follow-up visits and additional PFTs were scheduled as 
deemed appropriate. 
Redundant	PFTs	were	defined	as	tests	that	were	not	absolutely	necessary	to	
establish	a	final	diagnosis.	For	example,	a	reversible	obstructive	PFT	made	
the	histamine	provocation	 test	 redundant,	whereas	a	normal	flow	volume	
curve made the reversibility test redundant.
The economic analysis was conducted from a health care perspective that 
included only direct medical costs. Where available, unit cost prices were 
derived from a national guideline for the economic analysis of health care 
services [9]. In other instances, real cost prices were calculated on the basis 
of hospital administration data (Table 1).
.
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Table 1: The cost of PFTs and follow-up visits
Statistical analysis
The unpaired t-test with Welch’s correction was used to test for the statistical 
significance	 of	 differences	 between	 the	 two	groups.	An	 alpha	 of	 0.05	 or	
less	was	considered	to	be	significant.	For	statistical	calculations,	we	used	
GraphPad Prism5 for Microsoft Windows (www.graphpad.com).
Results
From a total of 183 patients, 179 patients were included in this study: 86 
patients in the CG and 93 patients in the EG. Four patients were excluded 
for the following reasons: one patient had a malignancy, one patient failed 
to follow-up, one patient died within a week of the start of the study, and the 
protocol was not followed with one patient. The second physician calibrated 
his	findings	with	 the	findings	of	 the	PFT-ordering	physician	only	if	 there	
were	conflicting	findings.	In	all	of	these	cases,	we	achieved	a	consensus	on	
the	final	diagnosis.
Table	 2	 summarizes	 patient	 characteristics	 at	 baseline.	 Classification	 of	
PFT	groups	on	the	basis	of	PFT	results	and	final	diagnoses	are	presented	
in Table 3. In the control group, 35 patients were sorted in the completely 
reversible obstructive (CRO) group versus 39 patients in the experimental 
group. For the non-reversible obstructive group, these numbers were eight 
and nine patients, respectively. For the partly-reversible obstructive group, 
these numbers were 12 and 14, respectively. 
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Table 2. Patient characteristics
Table 3. Classification on the basis of PFT results and final diagnoses
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Diagnosis in the normal PFT group consisted of sarcoidosis (1), 
gastroesophageal	 reflux	 (GER)	 (5),	 rhinitis	 and/or	 sinusitis	 (7),	
hyperventilation	 syndrome	 (3),	 persistent	 cough	 (15/21	were	 smokers	 or	
ex-smokers),	and	dyspnea	(3/8	were	smokers).	
On the basis of clinical assessment, 52 patients were found to have COPD 
with	the	following	classifications:	7	patients	in	GOLD	stage	1;	24	patients	
in stage 2; 13 patients in stage 3, and 8 patients in stage 4.
 
The total cost of the procedures that were used to reach a final diagnosis in 
patients who were suspected of having obstructive lung diseases.
In the control group, the mean total cost of testing and outpatient visits per 
diagnosis were €227.17, whereas, in the experimental group, this cost was 
€180.89 (Figure 2, P<0.001), which is a 20% reduction in cost.
Figure 2. Mean cost per patient per diagnosis. Redund.= Redundant.
The number and cost of outpatient visits until diagnosis
In	 the	 control	 group,	 two	 outpatient	 visits	 were	 needed	 to	 reach	 a	 final	
diagnosis in 71 patients, whereas 15 patients needed three outpatient visits 
(mean 2.17, median 2). In the experimental group, 90 patients had two 
visits, and 3 patients had three visits (mean 2.03, median 2). The difference 
in	 total	visits	between	 these	groups	was	statistically	significant	 (P=0.02).	
Mean costs were €88.80 in the control group and €83.00 in the experimental 
group (Figure 2, P=0.02). 
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The number and cost of the PFTs that were needed for diagnosis: 
In the control group, a mean number of 3.81 PFTs per patient was necessary 
in order to diagnose asthma or COPD. In the experimental group, a mean 
number of 2.94 tests was necessary (Figure 2, P<0.001). In the control and 
experimental groups, the mean costs of PFTs were €138.37 and €97.89, 
respectively (P<0.001).
The number and cost of the redundant PFTs that were used for diagnosis:
In the control group, a mean of 1.20 redundant PFTs per patient were 
performed. In the experimental group, a mean of 0.08 unnecessary PFTs 
were performed (P<0.001). The mean costs of redundant tests for diagnoses 
in the control and experimental groups were €51.35 and €3.30, respectively 
(Figure 2).
Histamine provocation tests and the added cost of reversibility testing were 
the two most important sources of redundant costs (Table 4). 
Table 4. Redundant pulmonary function tests (PFT).
Time until final diagnosis
In the control group, a mean number of 33.02 days was necessary to reach a 
final	diagnosis,	whereas	in	the	experimental	group,	a	mean	number	of	35.94	
days was needed (P=0.51). 
Post-hoc
We evaluated the added value in making a diagnosis of asthma using the 
steroid test in our patients. Conforming to the protocol, we needed 11 steroid 
tests in the control group and 10 steroid tests in the experimental group. 
Patient diagnoses did not change with the addition of these steroid tests.
109
The optimization of the diagnostic work-up
 7
Discussion
The	main	finding	of	our	study	is	that	the	introduction	of	a	problem-oriented	
protocol for ordering PFTs in patients with suspected obstructive pulmonary 
disease can reduce the number of redundant PFTs and outpatient visits, 
which results in a 20% decrease in costs without an increase in time to 
final	diagnosis.	Given	the	high	frequency	of	PFT	usage	for	the	diagnosis	of	
obstructive lung disease, this observed decrease in cost results in a substantial 
savings at a population level. In our practice of 600 patients per year with 
suspected obstructive lung disease, protocol-guided test ordering can lead to 
an annual cost reduction of €27,768 = €64.28 per patient. The most important 
part of these potential savings is a reduction in the need for reversibility 
testing	when	a	normal	flow	volume	curve	is	obtained	and	a	reduction	in	the	
need for the time-consuming and unpleasant hyperresponsiveness (PC20 
histamine) test when obstruction with reversibility is obtained. 
Our lung function protocol is based on the asthma and COPD guidelines 
[7] of the Netherlands and is within the ERS and ATS standards. [3,4,6,10] 
Therefore, many other countries can use our protocol with slight 
modifications.	Our	patients	with	 asthma	and	COPD	are	demographically	
similar to patients in other western European countries, the USA, and 
Canada. The only difference is that most patients were referred to us from 
a family doctor, as is typically the case in the UK; however, in some other 
countries, a family physician may be skipped more often. Therefore, a 
minor selection bias is possible; however, the diagnostic criteria for COPD 
or asthma do not depend on the patient’s physician. Of course, the skills and 
the tools are different between general practitioners (GPs) and pulmonary 
physicians; however, for this study, we included only the most basal lung 
function tests and omitted tests, such as exercise testing. These tests are not 
always	needed	to	confirm	a	diagnosis	of	asthma	or	COPD.	We	believe	that	
the protocol discussed herein could easily be followed by GPs or hospital 
physician assistants so long as they have access to these basic tests, thus, 
leading to potentially more health-care savings. 
As we stated before, some physicians have used the protocol-driven lung 
function protocol that we developed approximately three years prior to this 
study.	The	first	author	of	this	study	and	two	other	physicians	have	primarily	
followed the protocol-driven testing strategy. Two other physicians (one 
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senior and one junior) did not implement this protocol-driven testing 
strategy because they were not convinced of the ability of this protocol to 
save time and cost. 
We all agreed to perform this study, and the behavior of these two physicians 
did change after the completion of this study. 
Trainees stay for four years in our hospital, and, at the time of the study, 
we	had	five	trainees	in	all	stages	of	their	educational	processes.	We	asked	
our trainees to order according to a test-protocol rather than at their own 
discretion.	We	advised	them	that	this	would	be	more	efficient.	
The	protocol	allows	pulmonary	function	assistants	to	work	more	efficiently,	
which decreases the frequency that they need to interrupt the doctor, who 
will	 often	 be	 in	 a	 consultation.	 The	 workflow	 is	 based	 on	 our	 national	
guideline, which resembles the international guidelines of the ERS.
Steroid	tests	would	not	have	added	value	to	the	diagnostic	workflow	in	our	
patient group; hence, we doubted the need for such a test in a routine setting. 
After this study, we removed the steroid tests from the PFT protocol.
The total time in days to diagnosis was not different between the two groups; 
however, without waiting lists for the outpatient department and for PFT, 
we believe there will be a difference in time between the CG and the EG 
that favors the EG. 
We want to emphasize that international guidelines and several national 
guidelines do not recommend reversibility testing as a means to distinguish 
asthma from COPD, other than when lung function returns to normal limits. 
We used three pulmonary function groups as an intermediate; however, the 
final	diagnosis	of	asthma	or	COPD	(or	both)	can	only	be	made	when	the	full	
clinical context, in which PFTs are only a part, is considered. 
The prediction threshold of 9% is not a commonly accepted threshold 
for distinguishing asthma from COPD. We only use this criterion to 
distinguish	between	the	“non-reversible	obstructive”	and	“partly-reversible	
obstructive”	PFT	groups.	Internationally,	this	is	merely	one	method	that	can	
be used to make this distinction between these subgroups, and no consensus 
is available regarding which criterion is the best [6].
 A weakness in our study is the potential of a Hawthorne effect. The knowledge 
that they were involved in a trial may have affected the physicians’ behavior 
(test	ordering,	making	a	final	diagnosis).	The	only	way	to	avoid	this	problem	
is to retrospectively conduct the study, which would challenge its internal 
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validity. Therefore, we decided to conduct a random, parallel design so as to 
ensure internal validity (equivalence between groups, minimal likelihood of 
confounding); however, to the extent that our study suffered from a potential 
Hawthorne effect, this will most likely have resulted in an under-estimation 
of the impact of protocol-guided test ordering.
In order to minimize the impact of a potential Hawthorne effect, we 
discussed all of the results within our group after the inclusion period. Some 
doctors wanted to minimize patient return visits and ordered tests, which 
were regarded to be unnecessary during the second visit. 
Conclusion
Problem-orientated	PFT	ordering,	significantly	reduces	the	number	of	PFTs,	
the total cost, and the number of outpatient visits in the diagnosis of asthma 
and COPD.
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Summary
Basal  lung function tests are obligatory to diagnose asthma and COPD as 
can	be	derived	by	their	definitions:	
“	 (COPD)	 is	a	preventable	and	 treatable	disease	characterized	by	airflow	
limitation	 that	 is	 not	 fully	 reversible.	 The	 airflow	 limitation	 is	 usually	
progressive	 and	 is	 associated	 with	 an	 abnormal	 inflammatory	 response	
of the lungs to noxious particles or gases, primarily caused by cigarette 
smoking.	Although	 COPD	 affects	 the	 lungs,	 it	 also	 produces	 significant	
systemic	consequences	[1].”
“Asthma	is	a	disorder	defined	by	its	clinical,	physiological	and	pathological	
characteristics. 
The main physiological feature of asthma is episodic airway obstruction 
characterized	by	expiratory	airflow	limitation.[2]”
Forced	 expiratory	 volume	 in	 the	 first	 second	 (FEV1)	 may	 be	 the	 most	
important lung function parameter and is used as a measure of severity of 
airflow	obstruction.	It	is	however	disappointing	that	this	parameter	does	not	
correlate well with the dyspnea feeling of the patient. Arguments for this 
finding	are:
The weak association between the change in dyspnea (one of the major 
complaints in subjects with COPD) and the change in FEV1 or FVC after 
the use of bronchodilators and may be due to airway compression during 
forced expiration [3-7]
The absence of dyspnea at rest in patient with stable COPD,  and therefore 
an inability to improve after the use of  bronchodilators.
Inspiratory	parameters,	however,	are	not	influenced	by	the	above	mentioned	
airway compression. Therefore we are interested  in inspiratory parameters, 
in subjects with COPD. Inspiratory parameters could be more sensitive to 
interventions like bronchodilators because the airway collapse may obscure 
benefits	of	interventions	on	expiratory	parameters.	In	the	literature		O’Donnell	
and Taube [7,8]  give support for the idea that inspiratory parameters may 
be	more	 sensitive	 to	 find	 significant	 improvements	 after	 bronchodilators	
in patients with COPD. However, which method of obtaining inspiratory 
parameters	would	be	best	is	not	defined	in	the	literature.			
Because inspiratory parameters can be obtained after a fast expiration (Fe) 
or after a slow expiration (Se) we compared these methods in chapter two 
[9].In	 169	 patients	 with	 COPD,	 Forced	 Inspiratory	 volume	 in	 the	 first	
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second (FIV1) maneuvers were performed after a forced (FIV1-Fe) and a 
slow (FIV1-Se) expiration. We found that the variability of FIV1-Fe was 
greater than that of FIV1-Se. The mean difference between FIV1-Se and 
FIV1-Fe was 0.21 liters. The difference depended on the Global Initiative 
for Chronic Obstructive Lung Disease (GOLD[1] stage): the higher the 
GOLD stage, the greater the difference between the two techniques. The 
correlation	coefficient	between	FIV1-Se	and	FIV1-Fe	was	high,	but	there	
was a poor agreement between measurements within the same subject of 
these parameters (limits of agreement -0.52 to +0.94 liters). We concluded 
that the two methods measuring FIV1 may not be interchangeable and we 
prefer the FIV1-Se method because the variability was lower.
After selecting the method (FIV1-Se), we investigated the optimal number 
of the FIV1-Se manoeuvres out of 8 attempts and found that at least 5 FIV1-
Se manoeuvres are needed to get an acceptable FIV1. This number holds for 
all GOLD stages[9].
Apart from the importance of the FEV1 to measure severity of COPD, it is 
also the most frequently used parameter to measure hyperresponsiveness 
and reversibility after an intervention. Bronchodilator drugs are widely 
used in COPD patients and the effect of bronchodilators can be assessed by 
measuring the acute response (reversibility) of the drug of interest on FEV1. 
In	samples	of	patients	with	COPD	there	are	significant	improvements	in	FEV1	
both on beta mimetic as on parasympathicolytic drugs,  but in an individual 
patient it is hard to prove improvement based on the recommendations of 
the ERS-ATS taskforce for interpreting the response of bronchodilators 
on FEV1 [10]. Only about 11% [11,12]of patients with severe COPD 
responded when we followed the ERS-ATS criteria, being an improvement 
of at least 200 ml and 12% from initial value. In chapter three we explored 
these ERS-ATS criteria.  We  evaluated the literature and found that none of 
the referenced literature for these criteria, used the recommended method 
by Bland and Altman [4] for describing natural spread. Notably this Bland 
and Altman method was also recommended by the ATS-ERS taskforce [10]. 
The knowledge of the natural spread is important because only responses 
to bronchodilators beyond the natural spread or random variation (RV) can 
be attributed to the bronchodilator in an individual patient. We investigated 
whether the type of this natural spread (or RV) for FEV1 was homoscedastic 
or heteroscedastic. A homoscedastic scatter would reduce the chance of 
under- or overestimating the RV for low or high parameter values. Not 
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only the type of scatter but also the quantity of scatter expressed in the 
coefficient	of	 repeatability	 (CR)	 is	 important.	 In	our	 sample	of	79	 stable	
COPD	patients,	the	FEV1	was	measured	five	times	in	one	day.	FEV1	values	
taken within one hour were compared, the difference between the FEV1 
measurements was expressed as absolute change in liters or a relative change 
in percent of predicted value or percent of initial value. We found that the 
type of scatter was heteroscedastic for the FEV1 when the difference was 
expressed as an absolute value in liters. However, when the difference was 
expressed as the percent change from the initial value or predicted value, 
we found a homoscedastic scatter. The CR within one hour of the FEV1 
was 12% when expressed as the percent change from the initial value. 
Based	 on	 these	findings,	we	 conclude	 that	 the	 absolute	 200	ml=0.2	 liter	
criterion may be omitted and so  more patients with severe COPD will have 
significant	airway	responsiveness.
In Chapter 2, we already investigated which inspiratory maneuver would be 
best, now we can use this method to investigate the random variation (natural 
variability) of the inspiratory parameters. In chapter 4 we investigated the 
random variation (type and quantity) of inspiratory parameters in the same 
population as we did for the FEV1[13]. 
The forced inspiratory volume in 1 second (FIV1), inspiratory capacity 
(IC),	maximal	inspiratory	flow	at	50%		(MIF50)	and	peak	inspiratory	flow	
(PIF)	were	measured	five	times	in	one	day.	The	values	of	these	parameters,	
taken	within	one	hour	and	within	one	day	were	compared.	The	coefficient	
of repeatability (CR) was calculated and in addition, linear regression was 
performed to investigate the type of scatter (homo- or heteroscedastic) of 
the measured parameters. The type of scatter was heteroscedastic for all 
of the parameters when the differences were expressed as absolute values; 
however, when the differences were expressed as the percent change from 
the initial values, we found a more homoscedastic scatter like we found 
for the FEV1. The CR within one hour of each parameter expressed as the 
percent change from the initial value was: IC, 19%; FIV1, 14%; PIF, 18%; 
MEF50, 21%.
Now we have estimated   the random variation for expiratory and inspiratory 
parameters, it is opportune to measure changes in these parameters on 
several interventions, like short acting bronchodilators, histamine, pursed 
lip breathing and steroids. These interventions are also subject for another 
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thesis, except the pursed lips breathing which we described in chapter 5 [14] 
and the short acting bronchodilators discussed in chapter 6 [15].
In patients with severe chronic obstructive pulmonary disease (COPD), 
pursed-lips breathing (PLB) improves the pulmonary gas exchange and 
hyperinflation	measured	by	electro-optic	coupling.	The	response	to	PLB	in	
inspiratory lung function tests is not known yet. In chapter 5 we measured 
the	effect	of	PLB	on	inspiratory	parameters	in	thirty-five	subjects	with	stable	
COPD	and	a	forced	expiratory	volume	in	first	second	(FEV1)	<50%	of	the	
predicted value. Patients were tested for the following primary parameters 
before,  immediately after PLB, and 5 min after PLB: forced inspiratory 
vital	capacity,	inspiratory	capacity	(IC),	forced	inspiratory	volume	in	first	
second	(FIV1),	maximal	inspiratory	flow	at	50%	of	VC,	(MIF50)	and	peak	
inspiratory	flow	(PIF).	Patients	were	also	tested	for	secondary	parameters:	
vital capacity (VC), FEV1, breathing frequency (BF), end-tidal CO2 tension 
(ET-CO2), and oxygen saturation (SO2). 
Of	the	primary	parameters,	only	IC	improved	significantly	(89	ml	p=0.006);	
with regard to the secondary parameters, the mean SO2 improved by 1% (p 
=	0.005)	and	the	mean	ET-CO2	and	BF	decreased	significantly	to	3.2	mm	
Hg	and	3.1	breaths/min,	respectively.	After	5	min	the	effects	diminished.	
In chapter 6 the responsiveness of short-term bronchodilators were described 
on inspiratory lung function parameters (ILP),and FEV1[15]. 
The aim of this study was to assess the effects of inhaled salbutamol 400 
mcg, ipratropium 80 mcg and placebo on ILP and FEV1, and their relation 
with change in dyspnea feeling on a Visual Analogue Scale (VAS).
85 subjects with stable COPD participated in a cross-over, randomized, 
double-blind placebo-controlled study. Spirometry was performed before 
and after inhalation of salbutamol, ipratropium and placebo. Changes in 
dyspnea were measured with VAS.
All	ILP	and	FEV1	improved	significantly	on	bronchodilators,	except	FIF50	
after Ipratropium.  After both bronchodilators, percent changes from initial 
values in IC were higher than corresponding changes in FEV1, but the 
differences	were	not	significant	(all	p>0.06).
Mean	 VAS	 score	 after	 bronchodilators	 and	 placebo	 showed	 significant	
improvements	 in	 dyspnea	 feeling	but	 did	 not	 significantly	 correlate	with	
changes in lung function parameters. For each lung function parameter, 
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patients	were	further	classified	as	responder	(improvement	beyond	random	
variation) or non-responder according to the degree of the change from 
baseline.	Response	 rates	 did	 not	 significantly	 differ	 between	 the	 various	
ILP.	Also	 no	 significant	 differences	were	 found	 between	 responders	 and	
non- responders regarding dyspnoea after bronchodilators. This applied 
to all ILP as well as to FEV1. So in subjects with COPD, all ILP and 
FEV1	 showed,	 just	 like	 the	 VAS	 score,	 significant	 improvements	 after	
bronchodilators, adjusted for placebo effect. However ILP were not more 
sensitive than FEV1 in detecting responders to bronchodilators and for 
changes in dyspnea feeling.
Asthma and COPD are very common and lung function tests are mandatory 
to establish their diagnosis. Therefore, it is important that  lung function 
tests	are	effective	and	efficient	used,since		pulmonary	function	tests	(PFTs),	
together	with	clinical	visits,	are	the	major	contributors	to	the	overall	financial	
costs of diagnosing patients suspected of having obstructive lung diseases. 
In	 chapter	 7	 we	 assessed	 whether	 a	 specific	 diagnostic	 test	 protocol	
contributes to the optimization of the work-up of patients suspected of 
having asthma or COPD. A prospective, single-blind, and randomized 
controlled study was performed. In the control group (CG), all of the PFTs 
that were ordered by the lung specialist were carried out. In the experimental 
group	 (EG),	 specific	 PFTs	 were	 selected	 according	 to	 a	 protocol.	 The	
primary	 end	 point	 was	 the	 total	 costs	 of	 achieving	 a	 final	 diagnosis.	 
One hundred and seventy-nine patients were included into this study: 
86 in the CG and 93 in the EG. The mean number of tests to diagnosis 
was 3.8 in the CG versus 2.9 in the EG (P<0.001). The mean number 
of redundant PFTs before diagnosis was 1.2 in the CG versus 0.08 in 
the EG. The number of patients who required an additional outpatient 
visit to complete diagnosis was higher in the CG in comparison to the 
EG. The mean cost of work-up per diagnosis (including clinical visits 
and lungfunction tests) was €227 in the CG versus €181 in the EG. 
 In patients with suspected obstructive lung disease, protocol-driven, PFT-
based selection is more cost-effective than test selection at the discretion of 
lung physicians
119
Summary
 8
Discussion
The most important results described in this thesis can be summarized as 
follows:
Inspiratory parameters could better be assessed after a slow expiration than 
after a forced expiration.
Five inspiratory maneuvers were needed to get an optimal result.
We found an unwanted heteroscedastic spread for the FEV1 and inspiratory 
lung	 function	 parameters,	 if	 we	 expressed	 the	 change	 in	 liters	 or	 L/sec,	
however if we expressed the change in percentage form baseline value we 
found a more  preferred homoscedastic spread.
For	the	FEV1	parameter	we	did	not	find	evidence	for	the	200	ml	improvement	
criterion as stated by Pellegrino at al. Just 12% improvement from baseline 
value	is	needed	for	a	statistically	significant	improvement.
Inspiratory parameters were not better than  FEV1 in the ability to detect a 
response beyond the natural spread after short acting bronchodilators.
Pursed lips breathing resulted in an improved inspiratory capacity (a measure 
for	hyperinflation)	but	not	in	improved	lung	function	parameters	of	airflow.	
 In patients with suspected obstructive lung disease, protocol-driven, PFT-
based selection was more cost-effective than test selection at the discretion 
of lung physicians.
In chapter 6, we concluded that for routine lung function testing there is 
no need to test the inspiratory parameters extensively. Although inspiratory 
parameters	 improved	 significantly	 after	 bronchodilators,	 FEV1	 disclosed	
more responders (response beyond the random variation), than inspiratory 
parameters. In our study, the correlation between inspiratory parameters and 
dyspnea	scale	was	not	statistically	significant.	In	the	literature,	significant	
correlation between these parameters have been published. This discrepancy 
may be due to the fact that we selected COPD subjects in all stages of 
severity whereas Taube et al selected only more severe COPD patients. But 
even if we selected a subset of severe COPD patients (GOLD stage III and 
IV),	we	were	not	able	to	detect	a	significant	relation.	Another	explanation	
may	be	that	a	correlation	on	dyspnea	may	be	hard	to	find	in	subjects	with	
stable COPD because they  are mostly not short of breath at rest.
We also found that a lot of subjects with COPD were able to inspire within 
one second their whole vital capacity, so FIV1 may not be so sensitive at all 
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in detecting bronchodilator response and another parameter like FIV in half 
a second would be more appropriate.
Recommendations for further research
Further research is ongoing, including research on the response of inspiratory 
parameters after inhalational steroids long acting bronchodilators and 
histamine. During our study more questions arised to make our function 
protocol	more	efficient:	
can we integrate the fraction of NO in the expired air (FeNO) in the 
lungfunction protocol, and so diminish the need of histamine provocation 
tests which are not patient  friendly.   
for	responsiveness	testing,	is	it	valid	to	use	salbutamol	first	and	measured	
the response after 15 minutes immediately followed by ipratropium and 
measure the added value response 30 minutes later as we did, compared 
with salbutamol and ipratropium on different days?
For responsiveness testing, is it valid to use salbutamol and ipratropium 
in one gift and measure the responses of the two after 15 and 45 minutes 
respectively?
On inspiratory parameters we did not investigate the random variation of the 
inspiratory capacity before and after maximal voluntary ventilation. This 
could	be	important	to	investigate	dynamic	hyperinflation	that	is	correlated	
with dyspnea on exertion.
If we know the above mentioned random variation we are able to study 
interventions like short acting bronchodilators on the effect on dynamic 
hyperinflation	without	the	need	for	exercise	testing.
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Samenvatting
Basaal longfunctieonderzoek en met name spirometrie is noodzakelijk om 
tot de diagnose astma of COPD (Chronic Obstructive Pulmonary Disease) te 
komen,	hetgeen	ook	is	af	te	leiden	uit	de	definities	van	deze	aandoeningen:
“COPD	is	een	aandoening	die	men	kan	voorkomen	en	behandelen	en	wordt	
gekenmerkt door een beperking van de luchtstroom die niet volledig hersteld 
kan worden. De beperking van de luchtstroom neemt gewoonlijk steeds 
meer toe en gaat gepaard met een abnormale ontstekingsreactie van de 
long ten gevolge van schadelijke deeltjes of gassen in de inademingslucht, 
dit laatste  weer vooral als gevolg van het roken van sigaretten. Hoewel 
COPD primair een aandoening van de longen is, heeft het ook belangrijke 
consequenties	voor	andere	organen	en	de	psyche	[1].”
“Astma	 is	 een	 aandoening	 die	 wordt	 gedefinieerd	 door	 klinische,	
fysiologische, en pathologische kenmerken. Het belangrijkste fysiologische 
kenmerk is de in episoden (aanvallen) optredende luchtwegobstructie en 
daardoor	beperking	van	de	luchtstroom	[2]	”.	
De geforceerde uitademing in de eerste seconde na een volledige inademing 
(FEV1) is tot nu toe de belangrijkste longfunctieparameter die wordt 
gebruikt o.a. als maat voor de ernst van de luchtweg obstructie. Echter stemt 
de FEV1 weinig overeen met het gevoel van benauwdheid dat de patiënt 
met astma of COPD ervaart. Argumenten hiervoor zijn:
1. Bij patiënten met COPD is er een zwakke overeenstemming 
gevonden, voor en na het toedienen van luchtwegverwijders, 
tussen de verbetering in het gevoel van benauwdheid en de 
gemeten verbetering van de longfunctie en met name de FEV1 
[3-7]. Dit is mogelijk te wijten is aan de luchtwegcompressie 
gedurende de geforceerde uitademing (expiratie). 
2. Bij	patiënten	met	stabiel	COPD,	die	per	definitie	een	te	lage	FEV1	
hebben, komt de ervaring van kortademigheid in rust weinig voor. 
Kortademigheid kan dan ook niet verbeteren na inname van een 
luchtweg (bronchus) verwijdend medicament of een medicament 
dat de, bij ontsteking horende, zwelling (oedeem) vermindert, 
terwijl de FEV1 dan wel verbetert. Veel studies waaronder de onze 
werden verricht bij stabiele COPD patiënten.
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Spirometrische parameters bij de inademing (inspiratie) worden niet 
beïnvloed door de onder punt 1 hierboven genoemde luchtwegcompressie, 
maar kunnen wel beïnvloed worden door vernauwing ten gevolge van 
ontstekingsoedeem of samentrekken van de spieren in de wand van 
de luchtwegen. Juist daarom zijn wij geïnteresseerd in de zogenaamde 
inspiratoire parameters met name bij patiënten met COPD. Inspiratoire 
parameters zouden wel eens gevoeliger kunnen zijn dan expiratoire 
parameters zoals de FEV1, omdat de luchtwegcompressie bij de expiratie het 
effect van luchtwegverwijders zou kunnen maskeren. In de literatuur vinden 
we steun voor deze gedachte bij O’Donnell en Taube [7,8]. Zij vonden na het 
geven van bronchusverwijders, een veel sterkere overeenstemming, tussen 
de verbetering  in het gevoel van benauwdheid en de verbetering gevonden 
bij de inspiratoire longfunctie parameters (ILP) en met name het geforceerde 
inspiratoire volume in de eerste seconde na een volledige uitademing (FIV1) 
en de longcapaciteit na een normale uitademing (IC). In ons onderzoek 
trachten we de vraag te beantwoorden of inademingsparameters beter zijn 
dan de FEV1 om bronchusverwijding op de sporen. 
Onderzoek naar de inademings methode: 
Inspiratoire longfunctieparameters kunnen we op twee manieren meten: 
De eerste manier als onderdeel van de geforceerde luchtstroommeting 
waarbij de patiënt voorafgaand aan de meting rustig diep inademt en hierna 
achtereenvolgens geforceerd uitademt en inademt, dus een inademing na 
een geforceerde uitademing (Fe-methode = Forced expiration method) De 
tweede manier: we kunnen dezelfde ILP’s meten na een rustige uitademing 
(Se-methode = Slow expiration method). Beide methoden worden in de 
praktijk gebruikt, maar welke is de beste?
In hoofdstuk 2 staat ons onderzoek naar de inspiratiemethode beschreven 
[9]. Wij vonden dat de variabiliteit (het omgekeerde van stabiliteit) van de 
meting van de FIV1  het grootst was bij de Fe-methode en bovendien dat 
de Se-methode gemiddeld tot een hogere waarde leidde (verschil 0,21 liter). 
Tot slot vonden we dat het verschil tussen beide methoden afhankelijk was 
van de ernst van de COPD ingedeeld volgens de z.g. GOLD klasse [1], 
waarbij het verschil groter werd bij ernstiger vormen van COPD. Hoewel 
wij een uitstekende correlatie tussen beide methoden zagen, vonden we 
een te grote variatie tussen metingen binnen het individu. Daarom mogen 
beide methoden in de praktijk bij een patiënt zeker niet door elkaar gebruikt 
worden. Wij komen dus tot de conclusie dat we een voorkeur hebben voor 
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de Se-methode vanwege de  betere stabiliteit en het niet afhankelijk zijn van 
de mate van obstructie bij de COPD patiënt.
Nadat we de beste methode hadden gekozen, onderzochten we hoe vaak we 
de meting moeten herhalen om een redelijk betrouwbare (reproduceerbare) 
meting te krijgen en wij vonden dat 5 metingen per patiënt leidden tot een 
goed compromis tussen het aantal uit te voeren metingen en de maximaal 
bereikte FIV1 [9]. De mate van ernst (GOLD klasse) was niet van invloed 
op het aantal uit te voeren metingen.
Onderzoek naar de natuurlijke spreiding van de FEV1 
Behalve het belang van de FEV1-meting om de ernst van COPD vast te 
stellen, wordt de FEV1 ook gebruikt om de mate van gevoeligheid van 
de luchtwegen te meten na het toedienen van prikkelende stoffen en om 
de mate van verbetering (reversibiliteit) te meten na een interventie zoals 
het toedienen van bronchusverwijdende medicijnen. Uit onderzoek bij 
groepen	patiënten	met	COPD	is	gebleken	dat	er	een	statistisch	significante	
verbetering optrad na het geven van bronchus verwijdende medicijnen 
(de z.g. sympaticomimetica en parasympaticolytica). Bij de individuele 
patiënt	 is	 het	 echter	moeilijk	 een	 significante	 verbetering	 te	 bewijzen	 en	
dat geldt zeker voor de patiënt met een ernstig COPD. Indien we daarbij 
de aanbevelingen voor verbetering van de gezamenlijke Europese (ERS) 
en	Amerikaanse	wetenschappelijke	“longartsen”	vereniging	(ATS)	zouden	
opvolgen [10] voldoet slechts 11 % van de patiënten met ernstig COPD aan 
de criteria genoemd in deze aanbevelingen [11,12]. Deze aanbevelingen zijn: 
de FEV1 moet minimaal 12% verbeteren ten opzichte van de uitgangswaarde 
én met een minimum van 200 cc [10]. Met name dat laatste criterium wordt 
vaak niet gehaald bij patiënten met ernstig COPD. Longartsen zien veel 
patiënten met ernstig COPD. 
In hoofdstuk 3 van het proefschrift wordt het onderzoek  naar de natuurlijke 
spreiding van de FEV1 gepresenteerd. Wij onderzochten de literatuur 
genoemd in deze aanbeveling en die daarna is verschenen en vonden dat 
geen van de onderzoekers de door Bland en Altman [4] geadviseerde aanpak 
heeft gebruikt, terwijl deze methode van aanpak zelfs door de auteurs van de 
ATS-ERS taskforce aanbevolen werd [10]. Wij onderzochten bij patiënten 
met COPD de natuurlijke spreiding (RV=random variation) van de FEV1-
parameter	en	onderzochten	niet	alleen	de	mate	van	spreiding	(CR=coëfficiënt	
of repeatability). Daarnaast onderzochten we of deze spreiding afhankelijk 
127
Samenvatting
 9
1
was van de uitgangswaarde van de FEV1. We gebruikten hiervoor een 
methode die in de praktijk vaak wordt gebruikt om verbeteringen na een 
interventie uit te drukken, te weten: als absolute verbetering b.v. 200 ml, 
of als procentuele verbetering van de uitgangswaarde b.v. 12% of als 
procentuele verbetering ten opzichte van de voorspelde waarde b.v. 9%. 
Het type spreiding dat voor alle uitgangswaarden gelijk is noemen we 
homoscedastisch, het type dat afhankelijk is van de uitgangswaarde  noemen 
we heteroscedastisch. 
Het kennen van de natuurlijke spreiding is belangrijk omdat men bij een 
individuele patiënt alleen kan aantonen dat een medicament werkt, indien 
de verandering die optreedt na het toedienen ervan de natuurlijke spreiding 
(RV) overstijgt. Bij een homoscedastische spreiding hoeven we maar 1 
getal te kennen voor alle uitgangswaarden van de FEV1 b.v. 12%, maar 
bij een heteroscedastische spreiding is dit in feite onmogelijk, omdat bij 
iedere uitgangswaarde een andere spreidingsmaat van toepassing is. 
In een steekproef van 79 patiënten met COPD werd de FEV1 5 x binnen 
een dag gemeten. Het verschil in FEV1-waarden genomen met een uur 
tijdsverschil, werd berekend en de spreiding daarvan werd bepaald. We 
vonden dat het type spreiding homoscedastisch is indien we het verschil 
tussen de metingen uitdrukten als het percentage van de uitgangswaarde 
maar ook van het percentage van de voorspelde waarde. De spreiding was 
echter heteroscedastisch indien we het verschil uitdrukten in het verschil in 
liters.	We	vonden	voor	de	coëfficiënt	van	herhaalbaarheid	(CR)	dat	12	%	
een goede waarde is gezien vanuit de uitgangswaarde. Echter het criterium 
van 200 cc is niet zo waardevol vanwege de heteroscedastische spreiding, 
we kunnen in dat geval dus niet volstaan met één getal. De consequentie 
is dat indien we het 200 cc-criterium negeren bij patiënten met een ernstig 
COPD,	 er	 veel	 vaker	 een	 statistisch	 significante	 verbetering	 kan	worden	
gevonden na het toedienen van bronchusverwijders, dan mogelijk is met de 
aanbevelingen van de ERS en ATS.
Onderzoek naar de natuurlijke spreiding van de inspiratoire 
parameters.
In hoofdstuk 2 beschreven we al hoe we inspiratoire parameters het beste 
konden meten, in hoofdstuk 4 gaan we in op de natuurlijke spreiding (zowel 
het type als de mate) van de inspiratoire longfunctieparameters bij dezelfde 
groep patiënten als beschreven bij de FEV1. De volgende parameters 
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werden gemeten: het geforceerde inspiratory volume in 1 second (FIV1), 
inspiratory	 capacity	 (IC),	maximal	 inspiratory	 flow	 at	 50%	 	 (MIF50)	 en	
peak	inspiratory	flow	(PIF).	Ook	hierbij	vonden	we	voor	al	deze	parameters	
een heteroscedastische spreiding indien we verschillen uitdrukten in liters 
of liters per seconde. Een homoscedastische spreiding vonden we indien 
we uitgingen van de uitgangswaarde. Dus stellen we voor om net als bij de 
FEV1, de verschillen uit te drukken in percentage van de uitgangswaarde 
(een percentage van normaal is niet te geven omdat er geen geaccepteerde 
normaalwaarden beschikbaar zijn). Wij vonden voor de natuurlijke spreiding 
de volgende waarden: IC, 19%; FIV1, 14%; PIF, 18%; MEF50, 21%.
Effect van Pursed-lips breathing op ILP en FEV1.
Nu we de natuurlijke spreiding van de FEV1 en de inspiratoire parameters 
kennen, is het mogelijk deze parameters voor en na verschillende interventies 
te meten zoals het toedienen van kort werkende luchtwegverwijders, 
histamine provocatie en het met geperste lippen uitademen (PLB=pursed 
lips breathing). Dat laatste beschrijven we in hoofdstuk 5 [13] en de 
kortwerkende bronchusverwijders in hoofdstuk 6 [14].
Bij patiënten met COPD verbetert PLB de gasuitwisseling in de longen en de 
hyperinflatie	van	de	longen	gemeten	via	een	methode	die	met	elektro-optische	
koppeling werkt. Het effect van PLB op inspiratoire parameters was echter 
niet bekend. Wij maten dit effect in een groep  van 35 COPD patiënten met 
een ernstige luchtwegobstructie (FEV1< 50% van de voorspelde waarde). 
Wij maten vooraf,  onmiddellijk na  PLB, en nog eens 5 minuten later de 
volgende primaire parameters: forced inspiratory vital capacity (FIVC), 
inspiratory	capacity	(IC),	forced	inspiratory	volume	in	first	second	(FIV1),	
maximal	 inspiratory	flow	at	50%	of	VC,	 en	peak	 inspiratory	flow	 (PIF).	
Patiënten werden ook getest op de volgende secundaire parameters:vital 
capacity (VC), FEV1, adem frequentie  (BF), CO2 spanning aan het einde 
van een normale uitademing (ET-CO2) en de zuurstofsaturatie (SO2 ). SO2 
is een maat voor het zuurstof gehalte gemeten met een pulseoximeter. 
Van	 de	 primaire	 parameters	 verbeterde	 alleen	 de	 	 IC	 significant;	 van	 de	
secundaire parameters verbeterde de gemiddelde SO2 met 1% (p = 0.005) 
en de gemiddelde ET-CO2 en BF met 3.2 mm Hg en 3.1 ademteugen per 
minuut. Na 5 minuten waren deze effecten duidelijk minder. 
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Effect van kortwerkende bronchusverwijders op ILP en FEV1[14]. 
Het doel van deze studie was het effect te meten van salbutamol, ipratropium 
en placebo op de ILP en de FEV1 en dit effect vervolgens te vergelijken 
met veranderingen in het subjectieve gevoel van benauwdheid, gemeten 
op een visueel analoge schaal (VAS). Alle gemiddelde waarden van de 
ILP	en	de	FEV1	verbeterden	significant	na	toediening	van	de	medicijnen	
(met uitzondering van de FIF50 voor ipratropium) maar niet na toediening 
van de placebo. Het benauwdheidsgevoel verbeterde ook bij placebo 
toediening	significant	maar	we	vonden	in	tegenstelling	tot	Taube	et	al	,	geen	
significante	overeenstemming	tussen	de	VAS	en	de	verbetering	van	de	ILP	
na	 bronchusverwijders.	 Verder	 vonden	 we	 geen	 significante	 verschillen	
in het aantal patiënten dat meer dan de natuurlijke spreiding verbeterde 
(responders) op de inspiratoire parameters en op de FEV1. Getalsmatig 
vonden we zelfs meer responders met de  FEV1 .
Doelmatigheidsonderzoek.
Astma en COPD komen vaak voor en longfunctieonderzoek is noodzakelijk 
om de diagnose te bevestigen. Daarom is het belangrijk, voor het gemak van 
de patiënt maar ook uit kosten-overwegingen, dat dit onderzoek zo effectief 
en	efficiënt	mogelijk	wordt	uitgevoerd.	
Bezoeken op de polikliniek en longfunctietesten (LFT) vormen een 
belangrijk	 deel	 van	 de	 financiële	 lasten.	Om	 effectiever	 en	 efficiënter	 te	
werken stelden wij  een longfunctieprotocol op voor patiënten met een 
obstructieve longaandoening. Echter niet eerder was onderzocht of en in 
welke mate dit tot kostenbeheersing zou kunnen leiden. 
In hoofstuk 7 doen wij verslag van ons doelmatigheidsonderzoek. Een 
prospectief, enkel blind en gerandomiseerd onderzoek werd uitgevoerd. 
In de controle groep (CG) werden alle LFT die door de specialist waren 
aangekruist op de longfunctie-afdeling uitgevoerd. 
In de experimentele groep (EG) werden longfunctietesten uitgevoerd 
volgens het door ons opgestelde longfunctieprotocol. Het doel was de kosten 
die nodig waren om tot de uiteindelijke diagnose te komen te vergelijken. 
In totaal namen 179 patiënten met verdenking op een obstructief lijden 
deel aan de studie: 86 in de CG and 93 in de EG. Het gemiddelde aantal 
testen om tot een diagnose te komen was 3,8 in de CG versus 2,9 in the 
EG (P<0,001). Het gemiddelde aantal overbodige LFT voordat de diagnose 
gesteld kon worden  was 1.2 in de CG versus 0.08 in de EG. Het aantal 
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patiënten dat extra op de poli terug moest komen omdat de diagnose niet 
rond was, kwam hoger uit in de CG dan in de EG. De totale kosten per 
gestelde diagnose (van poli bezoeken en LFT) bedroegen €227 in de CG 
versus €181 in de EG. 
De conclusie was dat LFT volgens ons longfunctieprotocol doelmatiger 
zijn dan het aankruisen van LFT door artsen bij patiënten verdacht van een 
obstructieve longaandoening.
Discussie:
Dit proefschrift voegt volgens ons het volgende toe aan wat we al weten 
over het basale longfunctieonderzoek bij patiënten met COPD:
•	 Inspiratoire  longfunctieparameters kunnen beter bepaald worden na 
een rustige uitademing, dan na een geforceerde uitademing.
•	 Vijf inspiratoire longfunctieoefeningen zijn nodig om een optimaal 
resultaat te krijgen ten aanzien van betrouwbaarheid en haalbaarheid.
•	 De natuurlijke spreiding van de door ons onderzochte inspiratoire 
parameters en de FEV1 was ongewenst heteroscedastisch wanneer 
wij de verandering uitdrukten in liters of liters per seconde maar 
veel meer gewenst homoscedastisch wanneer we deze uitdrukten als 
percentage van de uitgangswaarde.
•	 We vonden geen aanwijzingen voor de validiteit van het ERS-ATS 
criterium van minimale verbetering van tenminste 200 cc voor de 
FEV1	 na	 bronchusverwijders	 van	 een	 significante	 verbetering	 te	
mogen spreken. 
•	 De inspiratoire parameters doen het niet beter dan de FEV1 om 
een	 significante	 verbetering	 aan	 te	 tonen	 (meer	 verbetering	 dan	
de natuurlijke spreiding) na het toedienen van kortwerkende 
luchtwegverwijders. 
•	 De	Pursed-lips	 adem-techniek	 resulteert	 alleen	 in	 een	 significante	
verbetering	van	de	inspiratoire	capaciteit	(een	maat	voor	hyperinflatie)	
maar niet van de longfunctie parameters die stroomsnelheid meten. 
•	 Bij patiënten verdacht voor een obstructieve longaandoening is het 
doelmatiger	 te	 werken	 met	 een	 gedefinieerd	 longfunctieprotocol	
dan dat artsen naar eigen inzicht los longfunctie-onderzoeken 
aankruisen.
om
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Op de vraag of inspiratoire longfunctieparameters gemeten bij patiënten 
met COPD veel toevoegen aan het routine longfunctieonderzoek waarbij 
vooral de FEV1 en FVC worden gemeten moet het antwoord ontkennend 
zijn. Wij concluderen dat voor routine longfunctieonderzoek er geen 
harde noodzaak bestaat om inspiratoire longfuncties te meten want met de 
FEV1	 vinden	we	minimaal	 evenveel	 patiënten	 die	 significant	 verbeteren	
op voorwaarde dat we alleen het criterium gebruiken van 12% verbetering 
t.o.v. de uitgangswaarde en het criterium van tenminste 200 cc laten varen. 
Dit was niet wat wij verwachtten of hoopten bij de aanvang van onze 
studies. Wij verwachtten dat inspiratoire longfunctieparameters het wel 
eens veel beter zouden kunnen doen. Een reden dat Taube et al. tot andere 
bevindingen kwamen is mogelijk de patiënten selectie.
Wij onderzochten meer patiënten met minder ernstig COPD, terwijl Taube 
een steekproef nam bij patiënten met een lager gemiddelde FEV1 t.o.v. de 
voorspelde waarde dan in onze steekproef.
Een tweede reden is dat wij alleen patiënten onderzochten met een stabiel 
COPD, dus die al enige tijd geen prednison of antibiotica nodig hadden. Een 
derde reden is dat veel patiënten met stabiel COPD geen kortademigheid in 
rust ervaren. Waarom zouden zij zich dan minder benauwd voelen na het 
geven van bronchusverwijders? Misschien was er wel verschil merkbaar 
geweest, als we keken naar kortademigheid bij inspanning maar dat hebben 
zowel Taube et al.en wij niet onderzocht. Tot slot vonden we dat bij een 
deel van onze COPD patiënten de vitale capaciteit al binnen de seconde 
was bereikt en dat maakt de FIV1 minder gevoelig om veranderingen te 
kunnen meten. Hoe Taube hier mee omging heeft hij niet beschreven. Het 
zou kunnen dat we dat probleem hadden kunnen ondervangen wanneer we 
niet van de FIV1 waren uitgegaan maar van de FIV in een halve seconde 
FIV1/2	.
Verder onderzoek:
De waarde van inspiratoire parameters bij verschillende interventies wordt 
door ons nog onderzocht, zoals bij toedienen van histamine, lang werkende 
bronchusverwijders en van inhalatiesteroiden of orale steroïden.
Gedurende de looptijd van onze studie werden meer vragen opgeroepen:
•	 Kunnen we in een aantal gevallen in plaats van de nogal 
belastende histamine provocatie test ook volstaan met de NO 
meting in de uitademingslucht en deze meting integreren in ons 
longfunctieprotocol?
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•	 Kunnen	we	om	de	reversibiliteitsmeting	efficiënter	te	maken	in	één	
keer zowel de reactie op salbutamol testen als de  daarna toegevoegde 
verbetering door middel van ipratropium?
•	 Kunnen	we	 om	 de	 reversibiliteitstest	 nog	 efficiënter	 te	maken	 in	
een keer zowel de salbutamol als de ipratropium toedienen en hun 
relatieve werking testen na respectievelijk 15 en 45 minuten?
•	 Wat is de natuurlijke spreiding voor en na maximale vrijwillege 
ventilatie van de inspiratoire capaciteit?
•	 Indien we de hierboven beschreven spreiding weten, kunnen we 
onderzoeken	of	deze	test	voor	dynamische	hyperinflatie	gevoeliger	
is dan de FEV1 om responders te vinden zonder de noodzaak 
hiervoor inspanningstesten te doen.
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aan het uiteindelijk artikel. Ben Pelzer en  Gert Jan van der Wilt, dank voor 
de ondersteuning betreffende methodiek en statistiek. Julius Jansen, jij zette 
ons aan tot het doelmatigheidsonderzoek en sprak met Richard en Yvonne 
over de ambitie een promotieonderzoek van het inspiratieproject te maken 
voor zowel Sunil als mij. 
Zonder metingen geen onderzoek, en dus ben ik dank verschuldigd aan 
Bard Kelder en Renate van Uden, die meedachten en soms onhaalbare 
hersenspinsels van Sunil en mij corrigeerden. Niet minder dank aan Nicole 
Gasperz, Stefanie Engelen en Katja van Hulsdonk; zij namen het gros van 
de metingen voor hun rekening.
Anneloes Niesink en Michiel Spanbroek hielpen mee met de dataverzameling 
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en schreven voor hun wetenschappelijke stage een verslag. Ook jullie 
hebben bijgedragen. Michiel, jij veel succes toegewenst met jouw 
desmosineonderzoek.
Ina Mulder (wetenschapsbureau CWZ) en Rigoni de Abreu  wil ik bedanken 
voor het nakijken van de inleiding en samenvatting in respectievelijk het 
Engels en Nederlands en Karien Pittie voor het dankwoord en curriculum 
vitae.
GlaxoSmithKline jullie hielpen ons zonder restricties met een bijdrage aan 
ons researchfonds.
Mijn maatschap heeft mij gesteund. Yvonne Berk nam na 2009 mijn taak 
als medisch manager over en ik heb weinig nieuwe taken daarvoor in 
de plaats gekregen. Willem van den Berg en Rob Janssen, jullie namen 
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bewogen door het overlijden van onze ouders, Elines oppas Louk van der 
Weerden, goede vriend Wim Westerhof en nichtje Eva. 
Mijn vrouw Marian en onze kinderen Fleur, Michiel en Eline en hun 
partners Wesley en Hedwich hebben me misschien wat te vaak achter 
de PC zien zitten. Eline, dank voor de mooie omslag van dit boekje; een 
foto die je maakte in Tenero aan het Lago Maggiore. Marian jij hebt mij 
altijd gesteund en dus ook weer in de afgelopen jaren en zeer geholpen bij 
de voorbereidingen voor het promotie feest. Ik ben trots op jou en onze 
kinderen. 
Mijn paranimfen dochter Fleur en vriend Jos Schulte, dank voor jullie 
praktische steun en het bijstaan tijdens de feestelijkheden.
Tot slot was het voor mij een zeer leerzame zoektocht in het land van de 
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het opschrijven van de verworven kennis. Maar gemiddeld heb ik ervan 
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